# Dossier zur Nutzenbewertung gemäß § 35a SGB V

*Tezepelumab (Tezspire®)*

AstraZeneca GmbH

## Modul 4 A – Anhang 4-G-4

*Add-on-Erhaltungstherapie bei Erwachsenen und Jugendlichen ab 12 Jahren mit schwerem Asthma, das trotz hochdosierter inhalativer Kortikosteroide plus eines weiteren Arzneimittels zur Erhaltungstherapie unzureichend kontrolliert ist*

UE-Analysen, ohne Berücksichtigung von erkrankungsbezogenen Ereignissen

Biomarker$_{low}$-Population

RCT mit dem zu bewertenden Arzneimittel

Stand: 11.11.2022

Table MT1AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 66 | 41 (62.1) [49.3, 73.8] | 48 | 32 (66.7) [51.6, 79.6] | 0.932 [0.708, 1.227] | 0.820 [0.376, 1.788] | -4.5 [-24.1, 15.0] | 0.694 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 02FEB2022

Table NT1AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 55 | 33 (60.0) [45.9, 73.0] | 40 | 27 (67.5) [50.9, 81.4] | 0.889 [0.655, 1.205] | 0.722 [0.308, 1.696] | -7.5 [-29.1, 14.1] | 0.522 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table NT1AA_TBMI0: Incidence of non-disease related TEAEs during study period
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 54 | 33 (61.1) [46.9, 74.1] | 39 | 26 (66.7) [49.8, 80.9] | 0.917 [0.674, 1.247] | 0.786 [0.332, 1.860] | -5.6 [-27.5, 16.3] | 0.665 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table PT3AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 12 | 8 (66.7) [34.9, 90.1] | 9 | 6 (66.7) [29.9, 92.5] | 1.000 [0.543, 1.843] | 1.000 [0.160, 6.255] | 0.0 [-50.5, 50.5] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table ST1AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 12 | 5 (41.7) [15.2, 72.3] | 11 | 6 (54.5) [23.4, 83.3] | 0.764 [0.323, 1.805] | 0.595 [0.114, 3.102] | -12.9 [-62.1, 36.4] | 0.684 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table DT1AA_UBMI0: Incidence of non-disease related TEAEs during study period
DSAFNB - LTE

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 45 | 33 (73.3) [58.1, 85.4] | 19 | 15 (78.9) [54.4, 93.9] | 0.929 [0.694, 1.243] | 0.733 [0.203, 2.653] | -5.6 [-31.8, 20.6] | 0.758 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table CT1AA_SBMI0: Incidence of non-disease related TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 4 | 3 (75.0) [19.4, 99.4] | 8 | 7 (87.5) [47.3, 99.7] | 0.857 [0.459, 1.599] | 0.429 [0.020, 9.364] | -12.5 [-79.5, 54.5] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table MT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.339 |
| Male | 20 | 11 (55.0) [31.5, 76.9] | 8 | 6 (75.0) [34.9, 96.8] | 0.733 [0.418, 1.288] | 0.407 [0.066, 2.531] | -20.0 [-65.8, 25.8] | 0.419 |
| Female | 46 | 30 (65.2) [49.8, 78.6] | 40 | 26 (65.0) [48.3, 79.4] | 1.003 [0.736, 1.368] | 1.010 [0.415, 2.456] | 0.2 [-22.3, 22.8] | 1.000 |
| Age | | | | | | | | 0.293 |
| < 65 years | 56 | 37 (66.1) [52.2, 78.2] | 39 | 26 (66.7) [49.8, 80.9] | 0.991 [0.741, 1.325] | 0.974 [0.410, 2.314] | -0.6 [-22.1, 20.9] | 1.000 |
| >= 65 years | 10 | 4 (40.0) [12.2, 73.8] | 9 | 6 (66.7) [29.9, 92.5] | 0.600 [0.247, 1.459] | 0.333 [0.051, 2.177] | -26.7 [-80.5, 27.1] | 0.370 |
| Exacerbations in the year before study | | | | | | | | 0.916 |
| <= 2 | 38 | 23 (60.5) [43.4, 76.0] | 31 | 20 (64.5) [45.4, 80.8] | 0.938 [0.651, 1.353] | 0.843 [0.316, 2.252] | -4.0 [-29.8, 21.9] | 0.806 |
| > 2 | 28 | 18 (64.3) [44.1, 81.4] | 17 | 12 (70.6) [44.0, 89.7] | 0.911 [0.603, 1.376] | 0.750 [0.205, 2.748] | -6.3 [-39.0, 26.4] | 0.752 |
| Race | | N<10 any level | | | | | | NE |
| White | 43 | 23 (53.5) [37.7, 68.8] | 36 | 24 (66.7) [49.0, 81.4] | | | | |
| Black or African American | 6 | 6 (100.0) [54.1, 100.0] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 6 | 4 (66.7) [22.3, 95.7] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Region | | | | | | | | 0.235 | |
| Europe | 21 | 13 (61.9) [38.4, 81.9] | 15 | 6 (40.0) [16.3, 67.7] | 1.548 [0.765, 3.131] | 2.438 [0.627, 9.473] | 21.9 [-16.2, 60.0] | 0.311 | |
| America | 21 | 12 (57.1) [34.0, 78.2] | 13 | 11 (84.6) [54.6, 98.1] | 0.675 [0.436, 1.045] | 0.242 [0.043, 1.377] | -27.5 [-62.6, 7.6] | 0.140 | |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 9 | 7 (77.8) [40.0, 97.2] | 0.791 [0.455, 1.377] | 0.457 [0.066, 3.144] | -16.2 [-63.6, 31.1] | 0.648 | |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.000 [0.599, 1.668] | 1.000 [0.153, 6.531] | 0.0 [-46.3, 46.3] | 1.000 | |
| BMI | | N<10 any level | | | | | | NE | |
| < 18.5 kg/m**2 | 2 | 2 (100.0) [15.8, 100.0] | 0 | | | | | | |
| 18.5 - < 25.0 kg/m**2 | 12 | 6 (50.0) [21.1, 78.9] | 11 | 8 (72.7) [39.0, 94.0] | | | | | |
| 25.0 - < 30.0 kg/m**2 | 24 | 13 (54.2) [32.8, 74.4] | 16 | 12 (75.0) [47.6, 92.7] | | | | | |
| >= 30.0 kg/m**2 | 28 | 20 (71.4) [51.3, 86.8] | 21 | 12 (57.1) [34.0, 78.2] | | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.044 | i |
| < 150 cells/uL | 37 | 26 (70.3) [53.0, 84.1] | 23 | 13 (56.5) [34.5, 76.8] | 1.243 [0.821, 1.883] | 1.818 [0.615, 5.379] | 13.7 [-14.8, 42.3] | 0.404 | |
| >= 150 cells/uL | 29 | 15 (51.7) [32.5, 70.6] | 25 | 19 (76.0) [54.9, 90.6] | 0.681 [0.449, 1.031] | 0.338 [0.105, 1.092] | -24.3 [-52.7, 4.2] | 0.092 | |
| Baseline specific perennial FEIA status | | | | | | | | 0.790 | |
| All negative | 39 | 25 (64.1) [47.2, 78.8] | 29 | 19 (65.5) [45.7, 82.1] | 0.978 [0.687, 1.393] | 0.940 [0.343, 2.573] | -1.4 [-27.4, 24.5] | 1.000 | |
| Any positive | 24 | 14 (58.3) [36.6, 77.9] | 17 | 11 (64.7) [38.3, 85.8] | 0.902 [0.554, 1.468] | 0.764 [0.212, 2.757] | -6.4 [-41.5, 28.7] | 0.753 | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 61 | 40 (65.6) [52.3, 77.3] | 44 | 29 (65.9) [50.1, 79.5] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| OCS at baseline | | | | | | | | 0.781 |
| Yes | 8 | 6 (75.0) [34.9, 96.8] | 7 | 6 (85.7) [42.1, 99.6] | 0.875 [0.530, 1.445] | 0.500 [0.035, 7.104] | -10.7 [-63.8, 42.3] | 1.000 |
| No | 58 | 35 (60.3) [46.6, 73.0] | 41 | 26 (63.4) [46.9, 77.9] | 0.952 [0.696, 1.301] | 0.878 [0.385, 2.003] | -3.1 [-24.5, 18.4] | 0.835 |
| LAMA use at baseline | | | | | | | | 0.302 |
| Yes | 15 | 10 (66.7) [38.4, 88.2] | 16 | 9 (56.3) [29.9, 80.2] | 1.185 [0.676, 2.077] | 1.556 [0.362, 6.690] | 10.4 [-30.1, 50.9] | 0.716 |
| No | 51 | 31 (60.8) [46.1, 74.2] | 32 | 23 (71.9) [53.3, 86.3] | 0.846 [0.621, 1.152] | 0.607 [0.234, 1.574] | -11.1 [-34.2, 12.0] | 0.351 |
| Tiotropium use at baseline | | | | | | | | 0.687 |
| Yes | 13 | 8 (61.5) [31.6, 86.1] | 15 | 9 (60.0) [32.3, 83.7] | 1.026 [0.565, 1.862] | 1.067 [0.233, 4.885] | 1.5 [-41.9, 45.0] | 1.000 |
| No | 53 | 33 (62.3) [47.9, 75.2] | 33 | 23 (69.7) [51.3, 84.4] | 0.893 [0.657, 1.215] | 0.717 [0.284, 1.813] | -7.4 [-30.3, 15.4] | 0.642 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.146 |
| Yes | 19 | 14 (73.7) [48.8, 90.9] | 14 | 8 (57.1) [28.9, 82.3] | 1.289 [0.761, 2.185] | 2.100 [0.482, 9.140] | 16.5 [-22.3, 55.4] | 0.459 |
| No | 47 | 27 (57.4) [42.2, 71.7] | 34 | 24 (70.6) [52.5, 84.9] | 0.814 [0.586, 1.130] | 0.563 [0.220, 1.436] | -13.1 [-36.5, 10.2] | 0.253 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Figure MF1AA_SBMF0: Forest plot for non-disease related TEAEs during study period
DSAFB




Test for heterogeneity - p-value: 0.803, I-square: 0.0 %

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of affected patients. RR = relative risk. CI = confidence interval.
Heterogeneity was investigated with Cochran Q test. NE = not evaluable.
Source tables: NT1AA_TBMI0, PT3AA_SBMI0, MT1AA_SBMI0

Table NT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Sex | | | | | | | | 0.347 |
| Male | 19 | 10 (52.6) [28.9, 75.6] | 8 | 6 (75.0) [34.9, 96.8] | 0.702 [0.391, 1.259] | 0.370 [0.059, 2.323] | -22.4 [-68.7, 24.0] | 0.405 |
| Female | 36 | 23 (63.9) [46.2, 79.2] | 32 | 21 (65.6) [46.8, 81.4] | 0.974 [0.685, 1.383] | 0.927 [0.342, 2.512] | -1.7 [-27.4, 24.0] | 1.000 |
| Age | | | | | | | | 0.376 |
| < 65 years | 46 | 29 (63.0) [47.5, 76.8] | 33 | 22 (66.7) [48.2, 82.0] | 0.946 [0.682, 1.312] | 0.853 [0.333, 2.182] | -3.6 [-27.5, 20.3] | 0.814 |
| >= 65 years | 9 | 4 (44.4) [13.7, 78.8] | 7 | 5 (71.4) [29.0, 96.3] | 0.622 [0.261, 1.482] | 0.320 [0.039, 2.618] | -27.0 [-86.3, 32.3] | 0.358 |
| Exacerbations in the year before study | | | | | | | | 0.513 |
| <= 2 | 31 | 20 (64.5) [45.4, 80.8] | 27 | 18 (66.7) [46.0, 83.5] | 0.968 [0.666, 1.406] | 0.909 [0.307, 2.696] | -2.2 [-30.1, 25.8] | 1.000 |
| > 2 | 24 | 13 (54.2) [32.8, 74.4] | 13 | 9 (69.2) [38.6, 90.9] | 0.782 [0.467, 1.311] | 0.525 [0.126, 2.185] | -15.1 [-53.0, 22.9] | 0.491 |
| Race | | N<10 any level | | | | | | NE |
| White | 34 | 17 (50.0) [32.4, 67.6] | 28 | 19 (67.9) [47.6, 84.1] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 3 | 1 (33.3) [0.8, 90.6] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 7 | 5 (71.4) [29.0, 96.3] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | | | | | | | 0.228 |
| Europe | 11 | 7 (63.6) [30.8, 89.1] | 10 | 4 (40.0) [12.2, 73.8] | 1.591 [0.659, 3.839] | 2.625 [0.450, 15.310] | 23.6 [-27.5, 74.8] | 0.395 |
| America | 20 | 10 (50.0) [27.2, 72.8] | 11 | 9 (81.8) [48.2, 97.7] | 0.611 [0.364, 1.027] | 0.222 [0.038, 1.298] | -31.8 [-70.5, 6.8] | 0.128 |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 10 | 8 (80.0) [44.4, 97.5] | 0.769 [0.453, 1.307] | 0.400 [0.059, 2.702] | -18.5 [-63.6, 26.6] | 0.405 |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 9 | 6 (66.7) [29.9, 92.5] | 1.091 [0.607, 1.962] | 1.333 [0.196, 9.083] | 6.1 [-44.6, 56.7] | 1.000 |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 3 | 2 (66.7) [9.4, 99.2] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 11 | 5 (45.5) [16.7, 76.6] | 8 | 6 (75.0) [34.9, 96.8] | | | | |
| 25.0 - < 30.0 kg/m**2 | 20 | 11 (55.0) [31.5, 76.9] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| >= 30.0 kg/m**2 | 21 | 15 (71.4) [47.8, 88.7] | 18 | 11 (61.1) [35.7, 82.7] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.117 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 22 | 13 (59.1) [36.4, 79.3] | 1.111 [0.723, 1.705] | 1.322 [0.431, 4.051] | 6.5 [-23.6, 36.7] | 0.775 |
| >= 150 cells/uL | 23 | 12 (52.2) [30.6, 73.2] | 18 | 14 (77.8) [52.4, 93.6] | 0.671 [0.422, 1.065] | 0.312 [0.078, 1.239] | -25.6 [-58.6, 7.4] | 0.114 |
| Baseline specific perennial FEIA status | | | | | | | | 0.771 |
| All negative | 33 | 21 (63.6) [45.1, 79.6] | 25 | 17 (68.0) [46.5, 85.1] | 0.936 [0.645, 1.358] | 0.824 [0.274, 2.473] | -4.4 [-32.4, 23.7] | 0.786 |
| Any positive | 22 | 12 (54.5) [32.2, 75.6] | 14 | 9 (64.3) [35.1, 87.2] | 0.848 [0.492, 1.465] | 0.667 [0.168, 2.645] | -9.7 [-48.2, 28.7] | 0.732 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 50 | 32 (64.0) [49.2, 77.1] | 38 | 26 (68.4) [51.3, 82.5] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| OCS at baseline | | | | | | | | 0.921 |
| Yes | 8 | 6 (75.0) [34.9, 96.8] | 7 | 6 (85.7) [42.1, 99.6] | 0.875 [0.530, 1.445] | 0.500 [0.035, 7.104] | -10.7 [-63.8, 42.3] | 1.000 |
| No | 47 | 27 (57.4) [42.2, 71.7] | 33 | 21 (63.6) [45.1, 79.6] | 0.903 [0.632, 1.289] | 0.771 [0.309, 1.926] | -6.2 [-30.4, 18.0] | 0.647 |
| LAMA use at baseline | | | | | | | | 0.403 |
| Yes | 15 | 10 (66.7) [38.4, 88.2] | 16 | 10 (62.5) [35.4, 84.8] | 1.067 [0.633, 1.797] | 1.200 [0.274, 5.247] | 4.2 [-35.9, 44.3] | 1.000 |
| No | 40 | 23 (57.5) [40.9, 73.0] | 24 | 17 (70.8) [48.9, 87.4] | 0.812 [0.561, 1.175] | 0.557 [0.189, 1.641] | -13.3 [-40.4, 13.8] | 0.424 |
| Tiotropium use at baseline | | | | | | | | 0.876 |
| Yes | 13 | 8 (61.5) [31.6, 86.1] | 15 | 10 (66.7) [38.4, 88.2] | 0.923 [0.528, 1.615] | 0.800 [0.170, 3.767] | -5.1 [-47.9, 37.7] | 1.000 |
| No | 42 | 25 (59.5) [43.3, 74.4] | 25 | 17 (68.0) [46.5, 85.1] | 0.875 [0.607, 1.263] | 0.692 [0.244, 1.962] | -8.5 [-35.2, 18.3] | 0.604 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_SBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.305 |
| Yes | 20 | 14 (70.0) [45.7, 88.1] | 14 | 9 (64.3) [35.1, 87.2] | 1.089 [0.671, 1.768] | 1.296 [0.303, 5.540] | 5.7 [-32.5, 43.9] | 1.000 |
| No | 35 | 19 (54.3) [36.6, 71.2] | 26 | 18 (69.2) [48.2, 85.7] | 0.784 [0.527, 1.167] | 0.528 [0.182, 1.532] | -14.9 [-42.5, 12.6] | 0.294 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_TBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.539 |
| Male | 18 | 10 (55.6) [30.8, 78.5] | 7 | 5 (71.4) [29.0, 96.3] | 0.778 [0.416, 1.453] | 0.500 [0.076, 3.293] | -15.9 [-66.4, 34.6] | 0.659 |
| Female | 36 | 23 (63.9) [46.2, 79.2] | 32 | 21 (65.6) [46.8, 81.4] | 0.974 [0.685, 1.383] | 0.927 [0.342, 2.512] | -1.7 [-27.4, 24.0] | 1.000 |
| Age | | | | | | | | 0.336 |
| < 65 years | 45 | 29 (64.4) [48.8, 78.1] | 32 | 21 (65.6) [46.8, 81.4] | 0.982 [0.705, 1.368] | 0.949 [0.367, 2.458] | -1.2 [-25.5, 23.1] | 1.000 |
| >= 65 years | 9 | 4 (44.4) [13.7, 78.8] | 7 | 5 (71.4) [29.0, 96.3] | 0.622 [0.261, 1.482] | 0.320 [0.039, 2.618] | -27.0 [-86.3, 32.3] | 0.358 |
| Exacerbations in the year before study | | | | | | | | 0.560 |
| <= 2 | 31 | 20 (64.5) [45.4, 80.8] | 26 | 17 (65.4) [44.3, 82.8] | 0.987 [0.673, 1.447] | 0.963 [0.323, 2.871] | -0.9 [-29.3, 27.5] | 1.000 |
| > 2 | 23 | 13 (56.5) [34.5, 76.8] | 13 | 9 (69.2) [38.6, 90.9] | 0.816 [0.490, 1.359] | 0.578 [0.137, 2.433] | -12.7 [-51.0, 25.6] | 0.501 |
| Race | | N<10 any level | | | | | | NE |
| White | 33 | 17 (51.5) [33.5, 69.2] | 28 | 19 (67.9) [47.6, 84.1] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 3 | 1 (33.3) [0.8, 90.6] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 6 | 4 (66.7) [22.3, 95.7] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_TBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | | | | | | | 0.280 |
| Europe | 11 | 7 (63.6) [30.8, 89.1] | 10 | 4 (40.0) [12.2, 73.8] | 1.591 [0.659, 3.839] | 2.625 [0.450, 15.310] | 23.6 [-27.5, 74.8] | 0.395 |
| America | 19 | 10 (52.6) [28.9, 75.6] | 11 | 9 (81.8) [48.2, 97.7] | 0.643 [0.386, 1.071] | 0.247 [0.042, 1.460] | -29.2 [-68.4, 10.0] | 0.140 |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 9 | 7 (77.8) [40.0, 97.2] | 0.791 [0.455, 1.377] | 0.457 [0.066, 3.144] | -16.2 [-63.6, 31.1] | 0.648 |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 9 | 6 (66.7) [29.9, 92.5] | 1.091 [0.607, 1.962] | 1.333 [0.196, 9.083] | 6.1 [-44.6, 56.7] | 1.000 |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 2 (100.0) [15.8, 100.0] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 11 | 5 (45.5) [16.7, 76.6] | 7 | 5 (71.4) [29.0, 96.3] | | | | |
| 25.0 - < 30.0 kg/m**2 | 20 | 11 (55.0) [31.5, 76.9] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| >= 30.0 kg/m**2 | 21 | 15 (71.4) [47.8, 88.7] | 18 | 11 (61.1) [35.7, 82.7] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.129 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 21 | 12 (57.1) [34.0, 78.2] | 1.148 [0.734, 1.796] | 1.432 [0.462, 4.437] | 8.5 [-22.3, 39.2] | 0.573 |
| >= 150 cells/uL | 22 | 12 (54.5) [32.2, 75.6] | 18 | 14 (77.8) [52.4, 93.6] | 0.701 [0.445, 1.105] | 0.343 [0.085, 1.380] | -23.2 [-56.6, 10.1] | 0.186 |
| Baseline specific perennial FEIA status | | | | | | | | 0.661 |
| All negative | 32 | 21 (65.6) [46.8, 81.4] | 24 | 16 (66.7) [44.7, 84.4] | 0.984 [0.674, 1.437] | 0.955 [0.312, 2.923] | -1.0 [-29.7, 27.6] | 1.000 |
| Any positive | 22 | 12 (54.5) [32.2, 75.6] | 14 | 9 (64.3) [35.1, 87.2] | 0.848 [0.492, 1.465] | 0.667 [0.168, 2.645] | -9.7 [-48.2, 28.7] | 0.732 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_TBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 49 | 32 (65.3) [50.4, 78.3] | 37 | 25 (67.6) [50.2, 82.0] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| OCS at baseline | | | | | | | | 0.823 |
| Yes | 8 | 6 (75.0) [34.9, 96.8] | 7 | 6 (85.7) [42.1, 99.6] | 0.875 [0.530, 1.445] | 0.500 [0.035, 7.104] | -10.7 [-63.8, 42.3] | 1.000 |
| No | 46 | 27 (58.7) [43.2, 73.0] | 32 | 20 (62.5) [43.7, 78.9] | 0.939 [0.654, 1.348] | 0.853 [0.338, 2.151] | -3.8 [-28.4, 20.8] | 0.816 |
| LAMA use at baseline | | | | | | | | 0.390 |
| Yes | 15 | 10 (66.7) [38.4, 88.2] | 15 | 9 (60.0) [32.3, 83.7] | 1.111 [0.643, 1.919] | 1.333 [0.301, 5.915] | 6.7 [-34.4, 47.7] | 1.000 |
| No | 39 | 23 (59.0) [42.1, 74.4] | 24 | 17 (70.8) [48.9, 87.4] | 0.833 [0.577, 1.201] | 0.592 [0.200, 1.755] | -11.9 [-39.1, 15.4] | 0.424 |
| Tiotropium use at baseline | | | | | | | | 0.852 |
| Yes | 13 | 8 (61.5) [31.6, 86.1] | 14 | 9 (64.3) [35.1, 87.2] | 0.957 [0.536, 1.711] | 0.889 [0.186, 4.244] | -2.7 [-46.6, 41.1] | 1.000 |
| No | 41 | 25 (61.0) [44.5, 75.8] | 25 | 17 (68.0) [46.5, 85.1] | 0.897 [0.623, 1.290] | 0.735 [0.258, 2.099] | -7.0 [-33.9, 19.8] | 0.608 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AA_TBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.198 |
| Yes | 19 | 14 (73.7) [48.8, 90.9] | 13 | 8 (61.5) [31.6, 86.1] | 1.197 [0.721, 1.988] | 1.750 [0.385, 7.951] | 12.1 [-27.4, 51.7] | 0.699 |
| No | 35 | 19 (54.3) [36.6, 71.2] | 26 | 18 (69.2) [48.2, 85.7] | 0.784 [0.527, 1.167] | 0.528 [0.182, 1.532] | -14.9 [-42.5, 12.6] | 0.294 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table DT1AA_UBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.554 |
| Male | 17 | 12 (70.6) [44.0, 89.7] | 2 | 1 (50.0) [1.3, 98.7] | 1.412 [0.341, 5.838] | 2.400 [0.124, 46.391] | 20.6 [-80.0, 100.0] | 1.000 |
| Female | 28 | 21 (75.0) [55.1, 89.3] | 17 | 14 (82.4) [56.6, 96.2] | 0.911 [0.670, 1.238] | 0.643 [0.142, 2.916] | -7.4 [-36.3, 21.6] | 0.719 |
| Age | | | | | | | | 0.329 |
| < 65 years | 36 | 25 (69.4) [51.9, 83.7] | 16 | 13 (81.3) [54.4, 96.0] | 0.855 [0.621, 1.177] | 0.524 [0.124, 2.218] | -11.8 [-40.7, 17.0] | 0.506 |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | 1.333 [0.580, 3.066] | 4.000 [0.167, 95.756] | 22.2 [-57.2, 100.0] | 0.455 |
| Exacerbations in the year before study | | | | | | | | 0.308 |
| <= 2 | 26 | 20 (76.9) [56.4, 91.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.058 [0.696, 1.608] | 1.250 [0.250, 6.255] | 4.2 [-33.2, 41.6] | 1.000 |
| > 2 | 19 | 13 (68.4) [43.4, 87.4] | 8 | 7 (87.5) [47.3, 99.7] | 0.782 [0.523, 1.169] | 0.310 [0.031, 3.111] | -19.1 [-59.0, 20.8] | 0.633 |
| Race | | N<10 any level | | | | | | NE |
| White | 31 | 20 (64.5) [45.4, 80.8] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Asian | 8 | 7 (87.5) [47.3, 99.7] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_UBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | N<10 any level | | | | | | NE |
| Europe | 9 | 8 (88.9) [51.8, 99.7] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| America | 19 | 10 (52.6) [28.9, 75.6] | 4 | 4 (100.0) [39.8, 100.0] | | | | |
| Asia/Pacific | 6 | 5 (83.3) [35.9, 99.6] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Rest of the world | 11 | 10 (90.9) [58.7, 99.8] | 6 | 5 (83.3) [35.9, 99.6] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 1 (50.0) [1.3, 98.7] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 6 | 4 (66.7) [22.3, 95.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| 25.0 - < 30.0 kg/m**2 | 18 | 14 (77.8) [52.4, 93.6] | 7 | 6 (85.7) [42.1, 99.6] | | | | |
| >= 30.0 kg/m**2 | 19 | 14 (73.7) [48.8, 90.9] | 9 | 7 (77.8) [40.0, 97.2] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.507 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| >= 150 cells/uL | 20 | 15 (75.0) [50.9, 91.3] | 9 | 8 (88.9) [51.8, 99.7] | 0.844 [0.599, 1.189] | 0.375 [0.037, 3.786] | -13.9 [-49.9, 22.1] | 0.633 |
| Baseline specific perennial FEIA status | | | | | | | | 0.434 |
| All negative | 27 | 20 (74.1) [53.7, 88.9] | 14 | 12 (85.7) [57.2, 98.2] | 0.864 [0.634, 1.177] | 0.476 [0.085, 2.677] | -11.6 [-41.7, 18.5] | 0.692 |
| Any positive | 18 | 13 (72.2) [46.5, 90.3] | 5 | 3 (60.0) [14.7, 94.7] | 1.204 [0.557, 2.602] | 1.733 [0.220, 13.670] | 12.2 [-48.2, 72.7] | 0.621 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_UBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 40 | 30 (75.0) [58.8, 87.3] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| High | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| OCS at baseline | | N<10 any level | | | | | | NE |
| Yes | 4 | 3 (75.0) [19.4, 99.4] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 41 | 30 (73.2) [57.1, 85.8] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| LAMA use at baseline | | | | | | | | 0.355 |
| Yes | 11 | 9 (81.8) [48.2, 97.7] | 7 | 5 (71.4) [29.0, 96.3] | 1.145 [0.664, 1.976] | 1.800 [0.191, 16.980] | 10.4 [-41.8, 62.6] | 1.000 |
| No | 34 | 24 (70.6) [52.5, 84.9] | 12 | 10 (83.3) [51.6, 97.9] | 0.847 [0.607, 1.182] | 0.480 [0.089, 2.596] | -12.7 [-44.4, 19.0] | 0.472 |
| Tiotropium use at baseline | | | | | | | | 0.985 |
| Yes | 9 | 7 (77.8) [40.0, 97.2] | 6 | 5 (83.3) [35.9, 99.6] | 0.933 [0.566, 1.539] | 0.700 [0.049, 10.014] | -5.6 [-59.8, 48.7] | 1.000 |
| No | 36 | 26 (72.2) [54.8, 85.8] | 13 | 10 (76.9) [46.2, 95.0] | 0.939 [0.655, 1.346] | 0.780 [0.177, 3.434] | -4.7 [-37.1, 27.7] | 1.000 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_UBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.670 |
| Yes | 15 | 13 (86.7) [59.5, 98.3] | 6 | 6 (100.0) [54.1, 100.0] | 0.867 [0.711, 1.057] | 0.415 + [0.017, 9.961] | -13.3 [-42.2, 15.5] | 1.000 |
| No | 30 | 20 (66.7) [47.2, 82.7] | 13 | 9 (69.2) [38.6, 90.9] | 0.963 [0.619, 1.498] | 0.889 [0.219, 3.609] | -2.6 [-38.3, 33.2] | 1.000 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table NT1AA_SBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 11 | 7 (63.6) [30.8, 89.1] | 13 | 7 (53.8) [25.1, 80.8] | | | | |
| North America | 15 | 8 (53.3) [26.6, 78.7] | 8 | 6 (75.0) [34.9, 96.8] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asia Pacific | 13 | 8 (61.5) [31.6, 86.1] | 7 | 5 (71.4) [29.0, 96.3] | | | | |
| Rest of the world | 7 | 5 (71.4) [29.0, 96.3] | 5 | 4 (80.0) [28.4, 99.5] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.117 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 22 | 13 (59.1) [36.4, 79.3] | 1.111 [0.723, 1.705] | 1.322 [0.431, 4.051] | 6.5 [-23.6, 36.7] | 0.775 |
| 150 - < 300 cells/uL | 23 | 12 (52.2) [30.6, 73.2] | 18 | 14 (77.8) [52.4, 93.6] | 0.671 [0.422, 1.065] | 0.312 [0.078, 1.239] | -25.6 [-58.6, 7.4] | 0.114 |
| Baseline eosinophils (cat. Q) | | | | | | | | 0.348 |
| Q1: < 140 cells/uL | 28 | 18 (64.3) [44.1, 81.4] | 22 | 13 (59.1) [36.4, 79.3] | 1.088 [0.698, 1.696] | 1.246 [0.395, 3.931] | 5.2 [-26.0, 36.4] | 0.774 |
| Q2: 140 - < 250 cells/uL | 23 | 13 (56.5) [34.5, 76.8] | 11 | 9 (81.8) [48.2, 97.7] | 0.691 [0.439, 1.088] | 0.289 [0.051, 1.646] | -25.3 [-62.5, 11.9] | 0.252 |
| Q3: 250 - < 430 cells/uL | 4 | 2 (50.0) [6.8, 93.2] | 7 | 5 (71.4) [29.0, 96.3] | 0.700 [0.236, 2.074] | 0.400 [0.031, 5.151] | -21.4 [-100.0, 57.6] | 0.576 |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 55 | 33 (60.0) [45.9, 73.0] | 40 | 27 (67.5) [50.9, 81.4] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AA_SBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFB

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. Q) | | | | | | | | 0.404 |
| Q1: < 16 ppb | 31 | 17 (54.8) [36.0, 72.7] | 26 | 18 (69.2) [48.2, 85.7] | 0.792 [0.526, 1.193] | 0.540 [0.181, 1.609] | -14.4 [-42.9, 14.1] | 0.290 |
| Q2: 16 - < 30 ppb | 24 | 16 (66.7) [44.7, 84.4] | 14 | 9 (64.3) [35.1, 87.2] | 1.037 [0.640, 1.680] | 1.111 [0.278, 4.434] | 2.4 [-34.7, 39.4] | 1.000 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 41 | 29 (70.7) [54.5, 83.9] | 34 | 23 (67.6) [49.5, 82.6] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 9 | 3 (33.3) [7.5, 70.1] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 2 (50.0) [6.8, 93.2] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| No | 51 | 31 (60.8) [46.1, 74.2] | 37 | 24 (64.9) [47.5, 79.8] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AA_TBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 11 | 7 (63.6) [30.8, 89.1] | 13 | 7 (53.8) [25.1, 80.8] | | | | |
| North America | 14 | 8 (57.1) [28.9, 82.3] | 8 | 6 (75.0) [34.9, 96.8] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asia Pacific | 13 | 8 (61.5) [31.6, 86.1] | 6 | 4 (66.7) [22.3, 95.7] | | | | |
| Rest of the world | 7 | 5 (71.4) [29.0, 96.3] | 5 | 4 (80.0) [28.4, 99.5] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.129 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 21 | 12 (57.1) [34.0, 78.2] | 1.148 [0.734, 1.796] | 1.432 [0.462, 4.437] | 8.5 [-22.3, 39.2] | 0.573 |
| 150 - < 300 cells/uL | 22 | 12 (54.5) [32.2, 75.6] | 18 | 14 (77.8) [52.4, 93.6] | 0.701 [0.445, 1.105] | 0.343 [0.085, 1.380] | -23.2 [-56.6, 10.1] | 0.186 |
| Baseline eosinophils (cat. Q) | | | | | | | | 0.366 |
| Q1: < 140 cells/uL | 28 | 18 (64.3) [44.1, 81.4] | 21 | 12 (57.1) [34.0, 78.2] | 1.125 [0.709, 1.786] | 1.350 [0.423, 4.304] | 7.1 [-24.6, 38.9] | 0.768 |
| Q2: 140 - < 250 cells/uL | 22 | 13 (59.1) [36.4, 79.3] | 11 | 9 (81.8) [48.2, 97.7] | 0.722 [0.463, 1.128] | 0.321 [0.056, 1.851] | -22.7 [-60.2, 14.8] | 0.258 |
| Q3: 250 - < 430 cells/uL | 4 | 2 (50.0) [6.8, 93.2] | 7 | 5 (71.4) [29.0, 96.3] | 0.700 [0.236, 2.074] | 0.400 [0.031, 5.151] | -21.4 [-100.0, 57.6] | 0.576 |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 54 | 33 (61.1) [46.9, 74.1] | 39 | 26 (66.7) [49.8, 80.9] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AA_TBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFB - adult

| Non-disease related TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. Q) | | | | | | | | 0.401 |
| Q1: < 16 ppb | 30 | 17 (56.7) [37.4, 74.5] | 26 | 18 (69.2) [48.2, 85.7] | 0.819 [0.546, 1.227] | 0.581 [0.193, 1.750] | -12.6 [-41.2, 16.1] | 0.412 |
| Q2: 16 - < 30 ppb | 24 | 16 (66.7) [44.7, 84.4] | 13 | 8 (61.5) [31.6, 86.1] | 1.083 [0.648, 1.812] | 1.250 [0.307, 5.085] | 5.1 [-33.3, 43.5] | 1.000 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 40 | 29 (72.5) [56.1, 85.4] | 33 | 22 (66.7) [48.2, 82.0] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 9 | 3 (33.3) [7.5, 70.1] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 2 (50.0) [6.8, 93.2] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| No | 50 | 31 (62.0) [47.2, 75.3] | 36 | 23 (63.9) [46.2, 79.2] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table DT1AA_UBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Age (cat. N) | | N<10 any level | | | | | | NE |
| < 18 years | 1 | 0 (0.0) [0.0, 97.5] | 0 | | | | | |
| 18 - < 65 years | 35 | 25 (71.4) [53.7, 85.4] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 9 | 8 (88.9) [51.8, 99.7] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| North America | 14 | 8 (57.1) [28.9, 82.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Asia Pacific | 6 | 5 (83.3) [35.9, 99.6] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Rest of the world | 7 | 7 (100.0) [59.0, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_UBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils (cat. N) | | | | | | | | 0.507 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| 150 - < 300 cells/uL | 20 | 15 (75.0) [50.9, 91.3] | 9 | 8 (88.9) [51.8, 99.7] | 0.844 [0.599, 1.189] | 0.375 [0.037, 3.786] | -13.9 [-49.9, 22.1] | 0.633 |
| Baseline eosinophils (cat. Q) | | N<10 any level | | | | | | NE |
| Q1: < 140 cells/uL | 21 | 14 (66.7) [43.0, 85.4] | 10 | 7 (70.0) [34.8, 93.3] | | | | |
| Q2: 140 - < 250 cells/uL | 21 | 17 (81.0) [58.1, 94.6] | 7 | 7 (100.0) [59.0, 100.0] | | | | |
| Q3: 250 - < 430 cells/uL | 3 | 2 (66.7) [9.4, 99.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_UBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 45 | 33 (73.3) [58.1, 85.4] | 19 | 15 (78.9) [54.4, 93.9] | | | | |
| Baseline FENO (cat. Q) | | | | | | | | 0.605 |
| Q1: < 16 ppb | 23 | 17 (73.9) [51.6, 89.8] | 12 | 9 (75.0) [42.8, 94.5] | 0.986 [0.656, 1.481] | 0.944 [0.190, 4.698] | -1.1 [-37.8, 35.6] | 1.000 |
| Q2: 16 - < 30 ppb | 22 | 16 (72.7) [49.8, 89.3] | 7 | 6 (85.7) [42.1, 99.6] | 0.848 [0.571, 1.261] | 0.444 [0.044, 4.503] | -13.0 [-54.3, 28.3] | 0.646 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_UBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 34 | 27 (79.4) [62.1, 91.3] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 6 | 3 (50.0) [11.8, 88.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 4 (100.0) [39.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 41 | 29 (70.7) [54.5, 83.9] | 18 | 14 (77.8) [52.4, 93.6] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table MT1AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 66 | 39 (59.1) [46.3, 71.0] | 48 | 31 (64.6) [49.5, 77.8] | 0.915 [0.685, 1.223] | 0.792 [0.367, 1.708] | -5.5 [-25.3, 14.3] | 0.566 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 02FEB2022

Table NT1AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 55 | 32 (58.2) [44.1, 71.3] | 40 | 26 (65.0) [48.3, 79.4] | 0.895 [0.650, 1.232] | 0.749 [0.323, 1.739] | -6.8 [-28.7, 15.0] | 0.530 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table NT1AAN_TBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 54 | 32 (59.3) [45.0, 72.4] | 39 | 25 (64.1) [47.2, 78.8] | 0.924 [0.670, 1.276] | 0.815 [0.348, 1.906] | -4.8 [-27.0, 17.3] | 0.672 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table PT3AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 12 | 7 (58.3) [27.7, 84.8] | 9 | 6 (66.7) [29.9, 92.5] | 0.875 [0.450, 1.701] | 0.700 [0.116, 4.232] | -8.3 [-59.6, 42.9] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table ST1AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 12 | 5 (41.7) [15.2, 72.3] | 11 | 6 (54.5) [23.4, 83.3] | 0.764 [0.323, 1.805] | 0.595 [0.114, 3.102] | -12.9 [-62.1, 36.4] | 0.684 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table DT1AAN_UBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFNB - LTE

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 45 | 33 (73.3) [58.1, 85.4] | 19 | 15 (78.9) [54.4, 93.9] | 0.929 [0.694, 1.243] | 0.733 [0.203, 2.653] | -5.6 [-31.8, 20.6] | 0.758 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table CT1AAN_SBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 4 | 3 (75.0) [19.4, 99.4] | 8 | 7 (87.5) [47.3, 99.7] | 0.857 [0.459, 1.599] | 0.429 [0.020, 9.364] | -12.5 [-79.5, 54.5] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table MT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Sex | | | | | | | | 0.396 |
| Male | 20 | 11 (55.0) [31.5, 76.9] | 8 | 6 (75.0) [34.9, 96.8] | 0.733 [0.418, 1.288] | 0.407 [0.066, 2.531] | -20.0 [-65.8, 25.8] | 0.419 |
| Female | 46 | 28 (60.9) [45.4, 74.9] | 40 | 25 (62.5) [45.8, 77.3] | 0.974 [0.698, 1.360] | 0.933 [0.390, 2.232] | -1.6 [-24.6, 21.3] | 1.000 |
| Age | | | | | | | | 0.312 |
| < 65 years | 56 | 35 (62.5) [48.5, 75.1] | 39 | 25 (64.1) [47.2, 78.8] | 0.975 [0.715, 1.330] | 0.933 [0.399, 2.181] | -1.6 [-23.5, 20.3] | 1.000 |
| >= 65 years | 10 | 4 (40.0) [12.2, 73.8] | 9 | 6 (66.7) [29.9, 92.5] | 0.600 [0.247, 1.459] | 0.333 [0.051, 2.177] | -26.7 [-80.5, 27.1] | 0.370 |
| Exacerbations in the year before study | | | | | | | | 0.751 |
| <= 2 | 38 | 22 (57.9) [40.8, 73.7] | 31 | 19 (61.3) [42.2, 78.2] | 0.945 [0.640, 1.395] | 0.868 [0.330, 2.286] | -3.4 [-29.6, 22.8] | 0.810 |
| > 2 | 28 | 17 (60.7) [40.6, 78.5] | 17 | 12 (70.6) [44.0, 89.7] | 0.860 [0.561, 1.319] | 0.644 [0.177, 2.339] | -9.9 [-42.8, 23.1] | 0.541 |
| Race | | N<10 any level | | | | | | NE |
| White | 43 | 21 (48.8) [33.3, 64.5] | 36 | 24 (66.7) [49.0, 81.4] | | | | |
| Black or African American | 6 | 6 (100.0) [54.1, 100.0] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Region | | | | | | | | 0.428 | |
| Europe | 21 | 11 (52.4) [29.8, 74.3] | 15 | 6 (40.0) [16.3, 67.7] | 1.310 [0.624, 2.750] | 1.650 [0.431, 6.313] | 12.4 [-26.1, 50.8] | 0.516 | |
| America | 21 | 12 (57.1) [34.0, 78.2] | 13 | 11 (84.6) [54.6, 98.1] | 0.675 [0.436, 1.045] | 0.242 [0.043, 1.377] | -27.5 [-62.6, 7.6] | 0.140 | |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 9 | 6 (66.7) [29.9, 92.5] | 0.923 [0.491, 1.735] | 0.800 [0.135, 4.745] | -5.1 [-55.1, 44.9] | 1.000 | |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.000 [0.599, 1.668] | 1.000 [0.153, 6.531] | 0.0 [-46.3, 46.3] | 1.000 | |
| BMI | | N<10 any level | | | | | | NE | |
| < 18.5 kg/m**2 | 2 | 2 (100.0) [15.8, 100.0] | 0 | | | | | | |
| 18.5 - < 25.0 kg/m**2 | 12 | 6 (50.0) [21.1, 78.9] | 11 | 7 (63.6) [30.8, 89.1] | | | | | |
| 25.0 - < 30.0 kg/m**2 | 24 | 12 (50.0) [29.1, 70.9] | 16 | 12 (75.0) [47.6, 92.7] | | | | | |
| >= 30.0 kg/m**2 | 28 | 19 (67.9) [47.6, 84.1] | 21 | 12 (57.1) [34.0, 78.2] | | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.026 | i |
| < 150 cells/uL | 37 | 25 (67.6) [50.2, 82.0] | 23 | 12 (52.2) [30.6, 73.2] | 1.295 [0.825, 2.032] | 1.910 [0.656, 5.563] | 15.4 [-13.5, 44.3] | 0.281 | |
| >= 150 cells/uL | 29 | 14 (48.3) [29.4, 67.5] | 25 | 19 (76.0) [54.9, 90.6] | 0.635 [0.411, 0.983] | 0.295 [0.091, 0.951] | -27.7 [-56.2, 0.7] | 0.052 | |
| Baseline specific perennial FEIA status | | | | | | | | 0.869 | |
| All negative | 39 | 23 (59.0) [42.1, 74.4] | 29 | 18 (62.1) [42.3, 79.3] | 0.950 [0.645, 1.399] | 0.878 [0.328, 2.352] | -3.1 [-29.6, 23.4] | 1.000 | |
| Any positive | 24 | 14 (58.3) [36.6, 77.9] | 17 | 11 (64.7) [38.3, 85.8] | 0.902 [0.554, 1.468] | 0.764 [0.212, 2.757] | -6.4 [-41.5, 28.7] | 0.753 | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 61 | 38 (62.3) [49.0, 74.4] | 44 | 28 (63.6) [47.8, 77.6] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| OCS at baseline | | | | | | | | 0.437 |
| Yes | 8 | 5 (62.5) [24.5, 91.5] | 7 | 6 (85.7) [42.1, 99.6] | 0.729 [0.394, 1.350] | 0.278 [0.022, 3.577] | -23.2 [-79.0, 32.6] | 0.569 |
| No | 58 | 34 (58.6) [44.9, 71.4] | 41 | 25 (61.0) [44.5, 75.8] | 0.961 [0.693, 1.333] | 0.907 [0.401, 2.052] | -2.4 [-24.0, 19.3] | 0.838 |
| LAMA use at baseline | | | | | | | | 0.294 |
| Yes | 15 | 9 (60.0) [32.3, 83.7] | 16 | 8 (50.0) [24.7, 75.3] | 1.200 [0.632, 2.278] | 1.500 [0.361, 6.230] | 10.0 [-31.3, 51.3] | 0.722 |
| No | 51 | 30 (58.8) [44.2, 72.4] | 32 | 23 (71.9) [53.3, 86.3] | 0.818 [0.597, 1.122] | 0.559 [0.216, 1.447] | -13.1 [-36.2, 10.1] | 0.251 |
| Tiotropium use at baseline | | | | | | | | 0.692 |
| Yes | 13 | 7 (53.8) [25.1, 80.8] | 15 | 8 (53.3) [26.6, 78.7] | 1.010 [0.506, 2.015] | 1.021 [0.230, 4.526] | 0.5 [-43.7, 44.7] | 1.000 |
| No | 53 | 32 (60.4) [46.0, 73.5] | 33 | 23 (69.7) [51.3, 84.4] | 0.866 [0.633, 1.185] | 0.663 [0.263, 1.669] | -9.3 [-32.3, 13.6] | 0.490 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.248 |
| Yes | 19 | 13 (68.4) [43.4, 87.4] | 14 | 8 (57.1) [28.9, 82.3] | 1.197 [0.693, 2.069] | 1.625 [0.387, 6.817] | 11.3 [-28.2, 50.8] | 0.716 |
| No | 47 | 26 (55.3) [40.1, 69.8] | 34 | 23 (67.6) [49.5, 82.6] | 0.818 [0.578, 1.156] | 0.592 [0.236, 1.486] | -12.3 [-36.1, 11.4] | 0.357 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Figure MF1AAN_SBMF0: Forest plot for non-disease related non-severe TEAEs during study period
DSAFB




Test for heterogeneity - p-value: 0.884, I-square: 0.0 %

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of affected patients. RR = relative risk. CI = confidence interval.
Heterogeneity was investigated with Cochran Q test. NE = not evaluable.
Source tables: NT1AAN_TBMI0, PT3AAN_SBMI0, MT1AAN_SBMI0

Table NT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.349 |
| Male | 19 | 10 (52.6) [28.9, 75.6] | 8 | 6 (75.0) [34.9, 96.8] | 0.702 [0.391, 1.259] | 0.370 [0.059, 2.323] | -22.4 [-68.7, 24.0] | 0.405 |
| Female | 36 | 22 (61.1) [43.5, 76.9] | 32 | 20 (62.5) [43.7, 78.9] | 0.978 [0.673, 1.421] | 0.943 [0.354, 2.513] | -1.4 [-27.5, 24.7] | 1.000 |
| Age | | | | | | | | 0.367 |
| < 65 years | 46 | 28 (60.9) [45.4, 74.9] | 33 | 21 (63.6) [45.1, 79.6] | 0.957 [0.676, 1.353] | 0.889 [0.353, 2.239] | -2.8 [-27.0, 21.5] | 0.819 |
| >= 65 years | 9 | 4 (44.4) [13.7, 78.8] | 7 | 5 (71.4) [29.0, 96.3] | 0.622 [0.261, 1.482] | 0.320 [0.039, 2.618] | -27.0 [-86.3, 32.3] | 0.358 |
| Exacerbations in the year before study | | | | | | | | 0.513 |
| <= 2 | 31 | 19 (61.3) [42.2, 78.2] | 27 | 17 (63.0) [42.4, 80.6] | 0.973 [0.651, 1.456] | 0.931 [0.321, 2.699] | -1.7 [-30.2, 26.8] | 1.000 |
| > 2 | 24 | 13 (54.2) [32.8, 74.4] | 13 | 9 (69.2) [38.6, 90.9] | 0.782 [0.467, 1.311] | 0.525 [0.126, 2.185] | -15.1 [-53.0, 22.9] | 0.491 |
| Race | | N<10 any level | | | | | | NE |
| White | 34 | 16 (47.1) [29.8, 64.9] | 28 | 19 (67.9) [47.6, 84.1] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 3 | 1 (33.3) [0.8, 90.6] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Region | | | | | | | | 0.356 |
| Europe | 11 | 6 (54.5) [23.4, 83.3] | 10 | 4 (40.0) [12.2, 73.8] | 1.364 [0.537, 3.460] | 1.800 [0.318, 10.201] | 14.5 [-37.3, 66.4] | 0.670 |
| America | 20 | 10 (50.0) [27.2, 72.8] | 11 | 9 (81.8) [48.2, 97.7] | 0.611 [0.364, 1.027] | 0.222 [0.038, 1.298] | -31.8 [-70.5, 6.8] | 0.128 |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 10 | 7 (70.0) [34.8, 93.3] | 0.879 [0.487, 1.588] | 0.686 [0.119, 3.963] | -8.5 [-56.1, 39.2] | 1.000 |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 9 | 6 (66.7) [29.9, 92.5] | 1.091 [0.607, 1.962] | 1.333 [0.196, 9.083] | 6.1 [-44.6, 56.7] | 1.000 |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 3 | 2 (66.7) [9.4, 99.2] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 11 | 5 (45.5) [16.7, 76.6] | 8 | 5 (62.5) [24.5, 91.5] | | | | |
| 25.0 - < 30.0 kg/m**2 | 20 | 10 (50.0) [27.2, 72.8] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| >= 30.0 kg/m**2 | 21 | 15 (71.4) [47.8, 88.7] | 18 | 11 (61.1) [35.7, 82.7] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.050 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 22 | 12 (54.5) [32.2, 75.6] | 1.203 [0.762, 1.899] | 1.591 [0.523, 4.837] | 11.1 [-19.3, 41.4] | 0.571 |
| >= 150 cells/uL | 23 | 11 (47.8) [26.8, 69.4] | 18 | 14 (77.8) [52.4, 93.6] | 0.615 [0.376, 1.007] | 0.262 [0.066, 1.041] | -30.0 [-62.9, 3.0] | 0.063 |
| Baseline specific perennial FEIA status | | | | | | | | 0.751 |
| All negative | 33 | 20 (60.6) [42.1, 77.1] | 25 | 16 (64.0) [42.5, 82.0] | 0.947 [0.633, 1.416] | 0.865 [0.296, 2.534] | -3.4 [-32.0, 25.3] | 1.000 |
| Any positive | 22 | 12 (54.5) [32.2, 75.6] | 14 | 9 (64.3) [35.1, 87.2] | 0.848 [0.492, 1.465] | 0.667 [0.168, 2.645] | -9.7 [-48.2, 28.7] | 0.732 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 50 | 31 (62.0) [47.2, 75.3] | 38 | 25 (65.8) [48.6, 80.4] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| OCS at baseline | | | | | | | | 0.474 |
| Yes | 8 | 5 (62.5) [24.5, 91.5] | 7 | 6 (85.7) [42.1, 99.6] | 0.729 [0.394, 1.350] | 0.278 [0.022, 3.577] | -23.2 [-79.0, 32.6] | 0.569 |
| No | 47 | 27 (57.4) [42.2, 71.7] | 33 | 20 (60.6) [42.1, 77.1] | 0.948 [0.655, 1.371] | 0.878 [0.354, 2.173] | -3.2 [-27.6, 21.3] | 0.821 |
| LAMA use at baseline | | | | | | | | 0.447 |
| Yes | 15 | 9 (60.0) [32.3, 83.7] | 16 | 9 (56.3) [29.9, 80.2] | 1.067 [0.587, 1.939] | 1.167 [0.279, 4.871] | 3.8 [-37.4, 44.9] | 1.000 |
| No | 40 | 23 (57.5) [40.9, 73.0] | 24 | 17 (70.8) [48.9, 87.4] | 0.812 [0.561, 1.175] | 0.557 [0.189, 1.641] | -13.3 [-40.4, 13.8] | 0.424 |
| Tiotropium use at baseline | | | | | | | | 0.948 |
| Yes | 13 | 7 (53.8) [25.1, 80.8] | 15 | 9 (60.0) [32.3, 83.7] | 0.897 [0.468, 1.721] | 0.778 [0.173, 3.493] | -6.2 [-50.1, 37.8] | 1.000 |
| No | 42 | 25 (59.5) [43.3, 74.4] | 25 | 17 (68.0) [46.5, 85.1] | 0.875 [0.607, 1.263] | 0.692 [0.244, 1.962] | -8.5 [-35.2, 18.3] | 0.604 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_SBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.554 |
| Yes | 20 | 13 (65.0) [40.8, 84.6] | 14 | 9 (64.3) [35.1, 87.2] | 1.011 [0.610, 1.677] | 1.032 [0.247, 4.303] | 0.7 [-38.0, 39.4] | 1.000 |
| No | 35 | 19 (54.3) [36.6, 71.2] | 26 | 17 (65.4) [44.3, 82.8] | 0.830 [0.549, 1.255] | 0.629 [0.221, 1.790] | -11.1 [-39.1, 16.9] | 0.438 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_TBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.538 |
| Male | 18 | 10 (55.6) [30.8, 78.5] | 7 | 5 (71.4) [29.0, 96.3] | 0.778 [0.416, 1.453] | 0.500 [0.076, 3.293] | -15.9 [-66.4, 34.6] | 0.659 |
| Female | 36 | 22 (61.1) [43.5, 76.9] | 32 | 20 (62.5) [43.7, 78.9] | 0.978 [0.673, 1.421] | 0.943 [0.354, 2.513] | -1.4 [-27.5, 24.7] | 1.000 |
| Age | | | | | | | | 0.325 |
| < 65 years | 45 | 28 (62.2) [46.5, 76.2] | 32 | 20 (62.5) [43.7, 78.9] | 0.996 [0.700, 1.415] | 0.988 [0.388, 2.519] | -0.3 [-24.9, 24.4] | 1.000 |
| >= 65 years | 9 | 4 (44.4) [13.7, 78.8] | 7 | 5 (71.4) [29.0, 96.3] | 0.622 [0.261, 1.482] | 0.320 [0.039, 2.618] | -27.0 [-86.3, 32.3] | 0.358 |
| Exacerbations in the year before study | | | | | | | | 0.553 |
| <= 2 | 31 | 19 (61.3) [42.2, 78.2] | 26 | 16 (61.5) [40.6, 79.8] | 0.996 [0.659, 1.505] | 0.990 [0.339, 2.887] | -0.2 [-29.2, 28.7] | 1.000 |
| > 2 | 23 | 13 (56.5) [34.5, 76.8] | 13 | 9 (69.2) [38.6, 90.9] | 0.816 [0.490, 1.359] | 0.578 [0.137, 2.433] | -12.7 [-51.0, 25.6] | 0.501 |
| Race | | N<10 any level | | | | | | NE |
| White | 33 | 16 (48.5) [30.8, 66.5] | 28 | 19 (67.9) [47.6, 84.1] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 3 | 1 (33.3) [0.8, 90.6] | | | | |
| Asian | 15 | 10 (66.7) [38.4, 88.2] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_TBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Region | | | | | | | | 0.417 |
| Europe | 11 | 6 (54.5) [23.4, 83.3] | 10 | 4 (40.0) [12.2, 73.8] | 1.364 [0.537, 3.460] | 1.800 [0.318, 10.201] | 14.5 [-37.3, 66.4] | 0.670 |
| America | 19 | 10 (52.6) [28.9, 75.6] | 11 | 9 (81.8) [48.2, 97.7] | 0.643 [0.386, 1.071] | 0.247 [0.042, 1.460] | -29.2 [-68.4, 10.0] | 0.140 |
| Asia/Pacific | 13 | 8 (61.5) [31.6, 86.1] | 9 | 6 (66.7) [29.9, 92.5] | 0.923 [0.491, 1.735] | 0.800 [0.135, 4.745] | -5.1 [-55.1, 44.9] | 1.000 |
| Rest of the world | 11 | 8 (72.7) [39.0, 94.0] | 9 | 6 (66.7) [29.9, 92.5] | 1.091 [0.607, 1.962] | 1.333 [0.196, 9.083] | 6.1 [-44.6, 56.7] | 1.000 |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 2 (100.0) [15.8, 100.0] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 11 | 5 (45.5) [16.7, 76.6] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| 25.0 - < 30.0 kg/m**2 | 20 | 10 (50.0) [27.2, 72.8] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| >= 30.0 kg/m**2 | 21 | 15 (71.4) [47.8, 88.7] | 18 | 11 (61.1) [35.7, 82.7] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.055 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 21 | 11 (52.4) [29.8, 74.3] | 1.253 [0.776, 2.022] | 1.736 [0.563, 5.346] | 13.2 [-17.7, 44.2] | 0.397 |
| >= 150 cells/uL | 22 | 11 (50.0) [28.2, 71.8] | 18 | 14 (77.8) [52.4, 93.6] | 0.643 [0.396, 1.045] | 0.286 [0.071, 1.148] | -27.8 [-61.2, 5.7] | 0.104 |
| Baseline specific perennial FEIA status | | | | | | | | 0.637 |
| All negative | 32 | 20 (62.5) [43.7, 78.9] | 24 | 15 (62.5) [40.6, 81.2] | 1.000 [0.664, 1.507] | 1.000 [0.335, 2.984] | 0.0 [-29.3, 29.3] | 1.000 |
| Any positive | 22 | 12 (54.5) [32.2, 75.6] | 14 | 9 (64.3) [35.1, 87.2] | 0.848 [0.492, 1.465] | 0.667 [0.168, 2.645] | -9.7 [-48.2, 28.7] | 0.732 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_TBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 49 | 31 (63.3) [48.3, 76.6] | 37 | 24 (64.9) [47.5, 79.8] | | | | |
| High | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| OCS at baseline | | | | | | | | 0.408 |
| Yes | 8 | 5 (62.5) [24.5, 91.5] | 7 | 6 (85.7) [42.1, 99.6] | 0.729 [0.394, 1.350] | 0.278 [0.022, 3.577] | -23.2 [-79.0, 32.6] | 0.569 |
| No | 46 | 27 (58.7) [43.2, 73.0] | 32 | 19 (59.4) [40.6, 76.3] | 0.989 [0.679, 1.439] | 0.972 [0.388, 2.434] | -0.7 [-25.5, 24.2] | 1.000 |
| LAMA use at baseline | | | | | | | | 0.417 |
| Yes | 15 | 9 (60.0) [32.3, 83.7] | 15 | 8 (53.3) [26.6, 78.7] | 1.125 [0.600, 2.109] | 1.313 [0.309, 5.583] | 6.7 [-35.4, 48.7] | 1.000 |
| No | 39 | 23 (59.0) [42.1, 74.4] | 24 | 17 (70.8) [48.9, 87.4] | 0.833 [0.577, 1.201] | 0.592 [0.200, 1.755] | -11.9 [-39.1, 15.4] | 0.424 |
| Tiotropium use at baseline | | | | | | | | 0.899 |
| Yes | 13 | 7 (53.8) [25.1, 80.8] | 14 | 8 (57.1) [28.9, 82.3] | 0.942 [0.479, 1.855] | 0.875 [0.191, 3.999] | -3.3 [-48.2, 41.6] | 1.000 |
| No | 41 | 25 (61.0) [44.5, 75.8] | 25 | 17 (68.0) [46.5, 85.1] | 0.897 [0.623, 1.290] | 0.735 [0.258, 2.099] | -7.0 [-33.9, 19.8] | 0.608 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table NT1AAN_TBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFB - adult

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.393 |
| Yes | 19 | 13 (68.4) [43.4, 87.4] | 13 | 8 (61.5) [31.6, 86.1] | 1.112 [0.656, 1.884] | 1.354 [0.309, 5.936] | 6.9 [-33.3, 47.1] | 0.721 |
| No | 35 | 19 (54.3) [36.6, 71.2] | 26 | 17 (65.4) [44.3, 82.8] | 0.830 [0.549, 1.255] | 0.629 [0.221, 1.790] | -11.1 [-39.1, 16.9] | 0.438 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11APR2022

Table DT1AAN_UBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.554 |
| Male | 17 | 12 (70.6) [44.0, 89.7] | 2 | 1 (50.0) [1.3, 98.7] | 1.412 [0.341, 5.838] | 2.400 [0.124, 46.391] | 20.6 [-80.0, 100.0] | 1.000 |
| Female | 28 | 21 (75.0) [55.1, 89.3] | 17 | 14 (82.4) [56.6, 96.2] | 0.911 [0.670, 1.238] | 0.643 [0.142, 2.916] | -7.4 [-36.3, 21.6] | 0.719 |
| Age | | | | | | | | 0.329 |
| < 65 years | 36 | 25 (69.4) [51.9, 83.7] | 16 | 13 (81.3) [54.4, 96.0] | 0.855 [0.621, 1.177] | 0.524 [0.124, 2.218] | -11.8 [-40.7, 17.0] | 0.506 |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | 1.333 [0.580, 3.066] | 4.000 [0.167, 95.756] | 22.2 [-57.2, 100.0] | 0.455 |
| Exacerbations in the year before study | | | | | | | | 0.308 |
| <= 2 | 26 | 20 (76.9) [56.4, 91.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.058 [0.696, 1.608] | 1.250 [0.250, 6.255] | 4.2 [-33.2, 41.6] | 1.000 |
| > 2 | 19 | 13 (68.4) [43.4, 87.4] | 8 | 7 (87.5) [47.3, 99.7] | 0.782 [0.523, 1.169] | 0.310 [0.031, 3.111] | -19.1 [-59.0, 20.8] | 0.633 |
| Race | | N<10 any level | | | | | | NE |
| White | 31 | 20 (64.5) [45.4, 80.8] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Asian | 8 | 7 (87.5) [47.3, 99.7] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_UBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | N<10 any level | | | | | | NE |
| Europe | 9 | 8 (88.9) [51.8, 99.7] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| America | 19 | 10 (52.6) [28.9, 75.6] | 4 | 4 (100.0) [39.8, 100.0] | | | | |
| Asia/Pacific | 6 | 5 (83.3) [35.9, 99.6] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Rest of the world | 11 | 10 (90.9) [58.7, 99.8] | 6 | 5 (83.3) [35.9, 99.6] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 1 (50.0) [1.3, 98.7] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 6 | 4 (66.7) [22.3, 95.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| 25.0 - < 30.0 kg/m**2 | 18 | 14 (77.8) [52.4, 93.6] | 7 | 6 (85.7) [42.1, 99.6] | | | | |
| >= 30.0 kg/m**2 | 19 | 14 (73.7) [48.8, 90.9] | 9 | 7 (77.8) [40.0, 97.2] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.507 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| >= 150 cells/uL | 20 | 15 (75.0) [50.9, 91.3] | 9 | 8 (88.9) [51.8, 99.7] | 0.844 [0.599, 1.189] | 0.375 [0.037, 3.786] | -13.9 [-49.9, 22.1] | 0.633 |
| Baseline specific perennial FEIA status | | | | | | | | 0.434 |
| All negative | 27 | 20 (74.1) [53.7, 88.9] | 14 | 12 (85.7) [57.2, 98.2] | 0.864 [0.634, 1.177] | 0.476 [0.085, 2.677] | -11.6 [-41.7, 18.5] | 0.692 |
| Any positive | 18 | 13 (72.2) [46.5, 90.3] | 5 | 3 (60.0) [14.7, 94.7] | 1.204 [0.557, 2.602] | 1.733 [0.220, 13.670] | 12.2 [-48.2, 72.7] | 0.621 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_UBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 40 | 30 (75.0) [58.8, 87.3] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| High | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| OCS at baseline | | N<10 any level | | | | | | NE |
| Yes | 4 | 3 (75.0) [19.4, 99.4] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 41 | 30 (73.2) [57.1, 85.8] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| LAMA use at baseline | | | | | | | | 0.355 |
| Yes | 11 | 9 (81.8) [48.2, 97.7] | 7 | 5 (71.4) [29.0, 96.3] | 1.145 [0.664, 1.976] | 1.800 [0.191, 16.980] | 10.4 [-41.8, 62.6] | 1.000 |
| No | 34 | 24 (70.6) [52.5, 84.9] | 12 | 10 (83.3) [51.6, 97.9] | 0.847 [0.607, 1.182] | 0.480 [0.089, 2.596] | -12.7 [-44.4, 19.0] | 0.472 |
| Tiotropium use at baseline | | | | | | | | 0.985 |
| Yes | 9 | 7 (77.8) [40.0, 97.2] | 6 | 5 (83.3) [35.9, 99.6] | 0.933 [0.566, 1.539] | 0.700 [0.049, 10.014] | -5.6 [-59.8, 48.7] | 1.000 |
| No | 36 | 26 (72.2) [54.8, 85.8] | 13 | 10 (76.9) [46.2, 95.0] | 0.939 [0.655, 1.346] | 0.780 [0.177, 3.434] | -4.7 [-37.1, 27.7] | 1.000 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_UBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.670 |
| Yes | 15 | 13 (86.7) [59.5, 98.3] | 6 | 6 (100.0) [54.1, 100.0] | 0.867 [0.711, 1.057] | 0.415 + [0.017, 9.961] | -13.3 [-42.2, 15.5] | 1.000 |
| No | 30 | 20 (66.7) [47.2, 82.7] | 13 | 9 (69.2) [38.6, 90.9] | 0.963 [0.619, 1.498] | 0.889 [0.219, 3.609] | -2.6 [-38.3, 33.2] | 1.000 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table NT1AAN_SBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFB

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 11 | 6 (54.5) [23.4, 83.3] | 13 | 7 (53.8) [25.1, 80.8] | | | | |
| North America | 15 | 8 (53.3) [26.6, 78.7] | 8 | 6 (75.0) [34.9, 96.8] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asia Pacific | 13 | 8 (61.5) [31.6, 86.1] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| Rest of the world | 7 | 5 (71.4) [29.0, 96.3] | 5 | 4 (80.0) [28.4, 99.5] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.050 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 22 | 12 (54.5) [32.2, 75.6] | 1.203 [0.762, 1.899] | 1.591 [0.523, 4.837] | 11.1 [-19.3, 41.4] | 0.571 |
| 150 - < 300 cells/uL | 23 | 11 (47.8) [26.8, 69.4] | 18 | 14 (77.8) [52.4, 93.6] | 0.615 [0.376, 1.007] | 0.262 [0.066, 1.041] | -30.0 [-62.9, 3.0] | 0.063 |
| Baseline eosinophils (cat. Q) | | | | | | | | 0.188 |
| Q1: < 140 cells/uL | 28 | 18 (64.3) [44.1, 81.4] | 22 | 12 (54.5) [32.2, 75.6] | 1.179 [0.736, 1.887] | 1.500 [0.479, 4.695] | 9.7 [-21.7, 41.1] | 0.567 |
| Q2: 140 - < 250 cells/uL | 23 | 12 (52.2) [30.6, 73.2] | 11 | 9 (81.8) [48.2, 97.7] | 0.638 [0.394, 1.031] | 0.242 [0.043, 1.377] | -29.6 [-67.0, 7.7] | 0.140 |
| Q3: 250 - < 430 cells/uL | 4 | 2 (50.0) [6.8, 93.2] | 7 | 5 (71.4) [29.0, 96.3] | 0.700 [0.236, 2.074] | 0.400 [0.031, 5.151] | -21.4 [-100.0, 57.6] | 0.576 |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 55 | 32 (58.2) [44.1, 71.3] | 40 | 26 (65.0) [48.3, 79.4] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AAN_SBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Baseline FENO (cat. Q) | | | | | | | | 0.658 |
| Q1: < 16 ppb | 31 | 17 (54.8) [36.0, 72.7] | 26 | 17 (65.4) [44.3, 82.8] | 0.839 [0.549, 1.282] | 0.643 [0.220, 1.881] | -10.5 [-39.4, 18.3] | 0.588 |
| Q2: 16 - < 30 ppb | 24 | 15 (62.5) [40.6, 81.2] | 14 | 9 (64.3) [35.1, 87.2] | 0.972 [0.591, 1.600] | 0.926 [0.235, 3.645] | -1.8 [-39.1, 35.6] | 1.000 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 41 | 29 (70.7) [54.5, 83.9] | 34 | 22 (64.7) [46.5, 80.3] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 9 | 2 (22.2) [2.8, 60.0] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 2 (50.0) [6.8, 93.2] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| No | 51 | 30 (58.8) [44.2, 72.4] | 37 | 23 (62.2) [44.8, 77.5] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AAN_TBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 11 | 6 (54.5) [23.4, 83.3] | 13 | 7 (53.8) [25.1, 80.8] | | | | |
| North America | 14 | 8 (57.1) [28.9, 82.3] | 8 | 6 (75.0) [34.9, 96.8] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 2 (50.0) [6.8, 93.2] | | | | |
| Asia Pacific | 13 | 8 (61.5) [31.6, 86.1] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| Rest of the world | 7 | 5 (71.4) [29.0, 96.3] | 5 | 4 (80.0) [28.4, 99.5] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.055 |
| < 150 cells/uL | 32 | 21 (65.6) [46.8, 81.4] | 21 | 11 (52.4) [29.8, 74.3] | 1.253 [0.776, 2.022] | 1.736 [0.563, 5.346] | 13.2 [-17.7, 44.2] | 0.397 |
| 150 - < 300 cells/uL | 22 | 11 (50.0) [28.2, 71.8] | 18 | 14 (77.8) [52.4, 93.6] | 0.643 [0.396, 1.045] | 0.286 [0.071, 1.148] | -27.8 [-61.2, 5.7] | 0.104 |
| Baseline eosinophils (cat. Q) | | | | | | | | 0.197 |
| Q1: < 140 cells/uL | 28 | 18 (64.3) [44.1, 81.4] | 21 | 11 (52.4) [29.8, 74.3] | 1.227 [0.750, 2.008] | 1.636 [0.516, 5.187] | 11.9 [-20.0, 43.8] | 0.558 |
| Q2: 140 - < 250 cells/uL | 22 | 12 (54.5) [32.2, 75.6] | 11 | 9 (81.8) [48.2, 97.7] | 0.667 [0.416, 1.069] | 0.267 [0.046, 1.530] | -27.3 [-65.0, 10.4] | 0.249 |
| Q3: 250 - < 430 cells/uL | 4 | 2 (50.0) [6.8, 93.2] | 7 | 5 (71.4) [29.0, 96.3] | 0.700 [0.236, 2.074] | 0.400 [0.031, 5.151] | -21.4 [-100.0, 57.6] | 0.576 |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 54 | 32 (59.3) [45.0, 72.4] | 39 | 25 (64.1) [47.2, 78.8] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table NT1AAN_TBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFB - adult

| Non-disease related non-severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. Q) | | | | | | | | 0.646 |
| Q1: < 16 ppb | 30 | 17 (56.7) [37.4, 74.5] | 26 | 17 (65.4) [44.3, 82.8] | 0.867 [0.570, 1.319] | 0.692 [0.234, 2.046] | -8.7 [-37.8, 20.3] | 0.589 |
| Q2: 16 - < 30 ppb | 24 | 15 (62.5) [40.6, 81.2] | 13 | 8 (61.5) [31.6, 86.1] | 1.016 [0.598, 1.725] | 1.042 [0.260, 4.181] | 1.0 [-37.7, 39.7] | 1.000 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 40 | 29 (72.5) [56.1, 85.4] | 33 | 21 (63.6) [45.1, 79.6] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 9 | 2 (22.2) [2.8, 60.0] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 1 (20.0) [0.5, 71.6] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 2 (50.0) [6.8, 93.2] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| No | 50 | 30 (60.0) [45.2, 73.6] | 36 | 22 (61.1) [43.5, 76.9] | | | | |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 09MAR2022

Table DT1AAN_UBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Age (cat. N) | | N<10 any level | | | | | | NE |
| < 18 years | 1 | 0 (0.0) [0.0, 97.5] | 0 | | | | | |
| 18 - < 65 years | 35 | 25 (71.4) [53.7, 85.4] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 9 | 8 (88.9) [51.8, 99.7] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| North America | 14 | 8 (57.1) [28.9, 82.3] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Asia Pacific | 6 | 5 (83.3) [35.9, 99.6] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Rest of the world | 7 | 7 (100.0) [59.0, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_UBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils (cat. N) | | | | | | | | 0.507 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| 150 - < 300 cells/uL | 20 | 15 (75.0) [50.9, 91.3] | 9 | 8 (88.9) [51.8, 99.7] | 0.844 [0.599, 1.189] | 0.375 [0.037, 3.786] | -13.9 [-49.9, 22.1] | 0.633 |
| Baseline eosinophils (cat. Q) | | N<10 any level | | | | | | NE |
| Q1: < 140 cells/uL | 21 | 14 (66.7) [43.0, 85.4] | 10 | 7 (70.0) [34.8, 93.3] | | | | |
| Q2: 140 - < 250 cells/uL | 21 | 17 (81.0) [58.1, 94.6] | 7 | 7 (100.0) [59.0, 100.0] | | | | |
| Q3: 250 - < 430 cells/uL | 3 | 2 (66.7) [9.4, 99.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_UBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 45 | 33 (73.3) [58.1, 85.4] | 19 | 15 (78.9) [54.4, 93.9] | | | | |
| Baseline FENO (cat. Q) | | | | | | | | 0.605 |
| Q1: < 16 ppb | 23 | 17 (73.9) [51.6, 89.8] | 12 | 9 (75.0) [42.8, 94.5] | 0.986 [0.656, 1.481] | 0.944 [0.190, 4.698] | -1.1 [-37.8, 35.6] | 1.000 |
| Q2: 16 - < 30 ppb | 22 | 16 (72.7) [49.8, 89.3] | 7 | 6 (85.7) [42.1, 99.6] | 0.848 [0.571, 1.261] | 0.444 [0.044, 4.503] | -13.0 [-54.3, 28.3] | 0.646 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_UBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 34 | 27 (79.4) [62.1, 91.3] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 6 | 3 (50.0) [11.8, 88.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 4 (100.0) [39.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 41 | 29 (70.7) [54.5, 83.9] | 18 | 14 (77.8) [52.4, 93.6] | | | | |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table MT1AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 66 | 7 (10.6) [4.4, 20.6] | 48 | 4 (8.3) [2.3, 20.0] | 1.273 [0.395, 4.104] | 1.305 [0.360, 4.736] | 2.3 [-10.3, 14.9] | 0.758 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 02FEB2022

Table NT1AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 55 | 4 (7.3) [2.0, 17.6] | 40 | 4 (10.0) [2.8, 23.7] | 0.727 [0.193, 2.735] | 0.706 [0.166, 3.010] | -2.7 [-16.4, 11.0] | 0.717 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table NT1AAC_TBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 54 | 4 (7.4) [2.1, 17.9] | 39 | 4 (10.3) [2.9, 24.2] | 0.722 [0.192, 2.712] | 0.700 [0.164, 2.989] | -2.8 [-16.9, 11.2] | 0.716 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table PT3AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 12 | 3 (25.0) [5.5, 57.2] | 9 | 0 (0.0) [0.0, 33.6] | 5.385 + [0.313, 92.735] | 7.000 + [0.316, 154.865] | 25.0 [-9.2, 59.2] | 0.229 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table ST1AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 12 | 2 (16.7) [2.1, 48.4] | 11 | 1 (9.1) [0.2, 41.3] | 1.833 [0.192, 17.512] | 2.000 [0.155, 25.755] | 7.6 [-28.2, 43.4] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table DT1AAC_UBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFNB - LTE

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 45 | 5 (11.1) [3.7, 24.1] | 19 | 3 (15.8) [3.4, 39.6] | 0.704 [0.187, 2.653] | 0.667 [0.142, 3.123] | -4.7 [-27.2, 17.9] | 0.685 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table CT1AAC_SBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 4 | 0 (0.0) [0.0, 60.2] | 8 | 2 (25.0) [3.2, 65.1] | 0.360 + [0.021, 6.117] | 0.289 + [0.011, 7.568] | -25.0 [-73.8, 23.8] | 0.515 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table MT1AAC_SBSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.993 |
| Male | 20 | 1 (5.0) [0.1, 24.9] | 8 | 0 (0.0) [0.0, 36.9] | 1.286 + [0.058, 28.651] | 1.308 + [0.048, 35.470] | 5.0 [-13.3, 23.3] | 1.000 |
| Female | 46 | 6 (13.0) [4.9, 26.3] | 40 | 4 (10.0) [2.8, 23.7] | 1.304 [0.396, 4.296] | 1.350 [0.352, 5.171] | 3.0 [-12.8, 18.8] | 0.745 |
| Age | | n<10 all levels | | | | | | NE |
| < 65 years | 56 | 6 (10.7) [4.0, 21.9] | 39 | 3 (7.7) [1.6, 20.9] | | | | |
| >= 65 years | 10 | 1 (10.0) [0.3, 44.5] | 9 | 1 (11.1) [0.3, 48.2] | | | | |
| Exacerbations in the year before study | | n<10 all levels | | | | | | NE |
| <= 2 | 38 | 4 (10.5) [2.9, 24.8] | 31 | 4 (12.9) [3.6, 29.8] | | | | |
| > 2 | 28 | 3 (10.7) [2.3, 28.2] | 17 | 0 (0.0) [0.0, 19.5] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAC_SBSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Race | | N<10 any level | | | | | | NE |
| White | 43 | 4 (9.3) [2.6, 22.1] | 36 | 2 (5.6) [0.7, 18.7] | | | | |
| Black or African American | 6 | 2 (33.3) [4.3, 77.7] | 4 | 0 (0.0) [0.0, 60.2] | | | | |
| Asian | 15 | 1 (6.7) [0.2, 31.9] | 6 | 1 (16.7) [0.4, 64.1] | | | | |
| Other | 2 | 0 (0.0) [0.0, 84.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Region | | n<10 all levels | | | | | | NE |
| Europe | 21 | 4 (19.0) [5.4, 41.9] | 15 | 2 (13.3) [1.7, 40.5] | | | | |
| America | 21 | 2 (9.5) [1.2, 30.4] | 13 | 0 (0.0) [0.0, 24.7] | | | | |
| Asia/Pacific | 13 | 1 (7.7) [0.2, 36.0] | 9 | 1 (11.1) [0.3, 48.2] | | | | |
| Rest of the world | 11 | 0 (0.0) [0.0, 28.5] | 11 | 1 (9.1) [0.2, 41.3] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 0 (0.0) [0.0, 84.2] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 12 | 2 (16.7) [2.1, 48.4] | 11 | 1 (9.1) [0.2, 41.3] | | | | |
| 25.0 - < 30.0 kg/m**2 | 24 | 3 (12.5) [2.7, 32.4] | 16 | 1 (6.3) [0.2, 30.2] | | | | |
| >= 30.0 kg/m**2 | 28 | 2 (7.1) [0.9, 23.5] | 21 | 2 (9.5) [1.2, 30.4] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAC_SBSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils - Low | | n<10 all levels | | | | | | NE |
| < 150 cells/uL | 37 | 5 (13.5) [4.5, 28.8] | 23 | 2 (8.7) [1.1, 28.0] | | | | |
| >= 150 cells/uL | 29 | 2 (6.9) [0.8, 22.8] | 25 | 2 (8.0) [1.0, 26.0] | | | | |
| Baseline specific perennial FEIA status | | | | | | | | 0.832 |
| All negative | 39 | 6 (15.4) [5.9, 30.5] | 29 | 4 (13.8) [3.9, 31.7] | 1.115 [0.346, 3.595] | 1.136 [0.289, 4.462] | 1.6 [-18.3, 21.5] | 1.000 |
| Any positive | 24 | 0 (0.0) [0.0, 14.2] | 17 | 0 (0.0) [0.0, 19.5] | 0.720 + [0.015, 34.616] | 0.714 + [0.014, 37.757] | -0.8 + [-14.9, 13.4] | NE |
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 61 | 7 (11.5) [4.7, 22.2] | 44 | 4 (9.1) [2.5, 21.7] | | | | |
| High | 5 | 0 (0.0) [0.0, 52.2] | 4 | 0 (0.0) [0.0, 60.2] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAC_SBSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| OCS at baseline | | | | | | | | 0.582 |
| Yes | 8 | 1 (12.5) [0.3, 52.7] | 7 | 0 (0.0) [0.0, 41.0] | 2.667 + [0.126, 56.626] | 3.000 + [0.105, 86.094] | 12.5 [-23.8, 48.8] | 1.000 |
| No | 58 | 6 (10.3) [3.9, 21.2] | 41 | 4 (9.8) [2.7, 23.1] | 1.060 [0.319, 3.521] | 1.067 [0.281, 4.050] | 0.6 [-13.5, 14.7] | 1.000 |
| LAMA use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 15 | 1 (6.7) [0.2, 31.9] | 16 | 2 (12.5) [1.6, 38.3] | | | | |
| No | 51 | 6 (11.8) [4.4, 23.9] | 32 | 2 (6.3) [0.8, 20.8] | | | | |
| Tiotropium use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 13 | 1 (7.7) [0.2, 36.0] | 15 | 2 (13.3) [1.7, 40.5] | | | | |
| No | 53 | 6 (11.3) [4.3, 23.0] | 33 | 2 (6.1) [0.7, 20.2] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAC_SBSIK: Incidence of non-disease related severe TEAEs during study period by key subgroups
DSAFB

| Non-disease related severe TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 19 | 2 (10.5) [1.3, 33.1] | 14 | 0 (0.0) [0.0, 23.2] | | | | |
| No | 47 | 5 (10.6) [3.5, 23.1] | 34 | 4 (11.8) [3.3, 27.5] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Figure MF1AAC_SBMF0: Forest plot for non-disease related severe TEAEs during study period
DSAFB




Test for heterogeneity - p-value: 0.210, I-square: 36.5 %

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of affected patients. RR = relative risk. CI = confidence interval.
Heterogeneity was investigated with Cochran Q test. NE = not evaluable.
Source tables: NT1AAC_TBMI0, PT3AAC_SBMI0, MT1AAC_SBMI0

Table MT1AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 66 | 5 (7.6) [2.5, 16.8] | 48 | 5 (10.4) [3.5, 22.7] | 0.727 [0.223, 2.373] | 0.705 [0.192, 2.585] | -2.8 [-15.4, 9.7] | 0.740 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 02FEB2022

Table NT1AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 55 | 3 (5.5) [1.1, 15.1] | 40 | 4 (10.0) [2.8, 23.7] | 0.545 [0.129, 2.303] | 0.519 [0.110, 2.461] | -4.5 [-17.8, 8.7] | 0.450 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table NT1AAS_TBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB - adult

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 54 | 3 (5.6) [1.2, 15.4] | 39 | 4 (10.3) [2.9, 24.2] | 0.542 [0.128, 2.284] | 0.515 [0.108, 2.443] | -4.7 [-18.2, 8.8] | 0.448 |

Note: DSAFB - adult = Dossier Biomarker Safety Set - adult.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 01FEB2022

Table PT3AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 12 | 2 (16.7) [2.1, 48.4] | 9 | 1 (11.1) [0.3, 48.2] | 1.500 [0.160, 14.083] | 1.600 [0.122, 20.993] | 5.6 [-33.6, 44.7] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table ST1AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 12 | 1 (8.3) [0.2, 38.5] | 11 | 3 (27.3) [6.0, 61.0] | 0.306 [0.037, 2.521] | 0.242 [0.021, 2.780] | -18.9 [-58.3, 20.4] | 0.317 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table DT1AAS_UBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFNB - LTE

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 45 | 6 (13.3) [5.1, 26.8] | 19 | 1 (5.3) [0.1, 26.0] | 2.533 [0.327, 19.639] | 2.769 [0.310, 24.730] | 8.1 [-9.8, 25.9] | 0.664 |

Note: DSAFNB - LTE = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table CT1AAS_SBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFB

| | Tezepelumab | | Placebo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 4 | 0 (0.0) [0.0, 60.2] | 8 | 1 (12.5) [0.3, 52.7] | 0.600 + [0.030, 12.150] | 0.556 + [0.018, 16.769] | -12.5 [-54.2, 29.2] | 1.000 |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: AAE, created on: 07FEB2022

Table MT1AAS_SBSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFB

| Non-disease related serious TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | n<10 all levels | | | | | | NE |
| Male | 20 | 2 (10.0) [1.2, 31.7] | 8 | 1 (12.5) [0.3, 52.7] | | | | |
| Female | 46 | 3 (6.5) [1.4, 17.9] | 40 | 4 (10.0) [2.8, 23.7] | | | | |
| Age | | n<10 all levels | | | | | | NE |
| < 65 years | 56 | 4 (7.1) [2.0, 17.3] | 39 | 4 (10.3) [2.9, 24.2] | | | | |
| >= 65 years | 10 | 1 (10.0) [0.3, 44.5] | 9 | 1 (11.1) [0.3, 48.2] | | | | |
| Exacerbations in the year before study | | n<10 all levels | | | | | | NE |
| <= 2 | 38 | 3 (7.9) [1.7, 21.4] | 31 | 3 (9.7) [2.0, 25.8] | | | | |
| > 2 | 28 | 2 (7.1) [0.9, 23.5] | 17 | 2 (11.8) [1.5, 36.4] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAS_SBSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFB

| Non-disease related serious TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Race | | N<10 any level | | | | | | NE |
| White | 43 | 3 (7.0) [1.5, 19.1] | 36 | 4 (11.1) [3.1, 26.1] | | | | |
| Black or African American | 6 | 1 (16.7) [0.4, 64.1] | 4 | 0 (0.0) [0.0, 60.2] | | | | |
| Asian | 15 | 1 (6.7) [0.2, 31.9] | 6 | 1 (16.7) [0.4, 64.1] | | | | |
| Other | 2 | 0 (0.0) [0.0, 84.2] | 2 | 0 (0.0) [0.0, 84.2] | | | | |
| Region | | n<10 all levels | | | | | | NE |
| Europe | 21 | 4 (19.0) [5.4, 41.9] | 15 | 1 (6.7) [0.2, 31.9] | | | | |
| America | 21 | 0 (0.0) [0.0, 16.1] | 13 | 1 (7.7) [0.2, 36.0] | | | | |
| Asia/Pacific | 13 | 1 (7.7) [0.2, 36.0] | 9 | 2 (22.2) [2.8, 60.0] | | | | |
| Rest of the world | 11 | 0 (0.0) [0.0, 28.5] | 11 | 1 (9.1) [0.2, 41.3] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 2 | 0 (0.0) [0.0, 84.2] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 12 | 2 (16.7) [2.1, 48.4] | 11 | 1 (9.1) [0.2, 41.3] | | | | |
| 25.0 - < 30.0 kg/m**2 | 24 | 1 (4.2) [0.1, 21.1] | 16 | 2 (12.5) [1.6, 38.3] | | | | |
| >= 30.0 kg/m**2 | 28 | 2 (7.1) [0.9, 23.5] | 21 | 2 (9.5) [1.2, 30.4] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAS_SBSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFB

| Non-disease related serious TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils - Low | | n<10 all levels | | | | | | NE |
| < 150 cells/uL | 37 | 3 (8.1) [1.7, 21.9] | 23 | 3 (13.0) [2.8, 33.6] | | | | |
| >= 150 cells/uL | 29 | 2 (6.9) [0.8, 22.8] | 25 | 2 (8.0) [1.0, 26.0] | | | | |
| Baseline specific perennial FEIA status | | n<10 all levels | | | | | | NE |
| All negative | 39 | 4 (10.3) [2.9, 24.2] | 29 | 3 (10.3) [2.2, 27.4] | | | | |
| Any positive | 24 | 1 (4.2) [0.1, 21.1] | 17 | 2 (11.8) [1.5, 36.4] | | | | |
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 61 | 5 (8.2) [2.7, 18.1] | 44 | 5 (11.4) [3.8, 24.6] | | | | |
| High | 5 | 0 (0.0) [0.0, 52.2] | 4 | 0 (0.0) [0.0, 60.2] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAS_SBSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFB

| Non-disease related serious TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| OCS at baseline | | n<10 all levels | | | | | | NE |
| Yes | 8 | 1 (12.5) [0.3, 52.7] | 7 | 1 (14.3) [0.4, 57.9] | | | | |
| No | 58 | 4 (6.9) [1.9, 16.7] | 41 | 4 (9.8) [2.7, 23.1] | | | | |
| LAMA use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 15 | 1 (6.7) [0.2, 31.9] | 16 | 2 (12.5) [1.6, 38.3] | | | | |
| No | 51 | 4 (7.8) [2.2, 18.9] | 32 | 3 (9.4) [2.0, 25.0] | | | | |
| Tiotropium use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 13 | 1 (7.7) [0.2, 36.0] | 15 | 2 (13.3) [1.7, 40.5] | | | | |
| No | 53 | 4 (7.5) [2.1, 18.2] | 33 | 3 (9.1) [1.9, 24.3] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Table MT1AAS_SBSIK: Incidence of non-disease related serious TEAEs during study period by key subgroups
DSAFB

| Non-disease related serious TEAEs during study period | Tezepelumab N | Tezepelumab n (%) [95 % CI] | Placebo N | Placebo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | n<10 all levels | | | | | | NE |
| Yes | 19 | 2 (10.5) [1.3, 33.1] | 14 | 1 (7.1) [0.2, 33.9] | | | | |
| No | 47 | 3 (6.4) [1.3, 17.5] | 34 | 4 (11.8) [3.3, 27.5] | | | | |

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 04APR2022

Figure MF1AAS_SBMF0: Forest plot for non-disease related serious TEAEs during study period
DSAFB




Test for heterogeneity - p-value: 0.453, I-square: 0.0 %

Note: DSAFB = Dossier Biomarker Safety Set.
N = total number of patients in analysis set. n = number of affected patients. RR = relative risk. CI = confidence interval.
Heterogeneity was investigated with Cochran Q test. NE = not evaluable.
Source tables: NT1AAS_TBMI0, PT3AAS_SBMI0, MT1AAS_SBMI0

Table DT1AA_LBMI0: Incidence of non-disease related TEAEs during study period
DSAFNB - LTE - adult

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related TEAEs during study period | 44 | 33 (75.0) [59.7, 86.8] | 19 | 15 (78.9) [54.4, 93.9] | 0.950 [0.712, 1.267] | 0.800 [0.219, 2.927] | -3.9 [-30.1, 22.2] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table DT1AA_LBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.499 |
| Male | 16 | 12 (75.0) [47.6, 92.7] | 2 | 1 (50.0) [1.3, 98.7] | 1.500 [0.365, 6.172] | 3.000 [0.150, 59.890] | 25.0 [-75.6, 100.0] | 0.490 |
| Female | 28 | 21 (75.0) [55.1, 89.3] | 17 | 14 (82.4) [56.6, 96.2] | 0.911 [0.670, 1.238] | 0.643 [0.142, 2.916] | -7.4 [-36.3, 21.6] | 0.719 |
| Age | | | | | | | | 0.359 |
| < 65 years | 35 | 25 (71.4) [53.7, 85.4] | 16 | 13 (81.3) [54.4, 96.0] | 0.879 [0.641, 1.205] | 0.577 [0.135, 2.469] | -9.8 [-38.7, 19.0] | 0.730 |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | 1.333 [0.580, 3.066] | 4.000 [0.167, 95.756] | 22.2 [-57.2, 100.0] | 0.455 |
| Exacerbations in the year before study | | | | | | | | 0.395 |
| <= 2 | 26 | 20 (76.9) [56.4, 91.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.058 [0.696, 1.608] | 1.250 [0.250, 6.255] | 4.2 [-33.2, 41.6] | 1.000 |
| > 2 | 18 | 13 (72.2) [46.5, 90.3] | 8 | 7 (87.5) [47.3, 99.7] | 0.825 [0.560, 1.217] | 0.371 [0.036, 3.838] | -15.3 [-55.2, 24.6] | 0.628 |
| Race | | N<10 any level | | | | | | NE |
| White | 30 | 20 (66.7) [47.2, 82.7] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Asian | 8 | 7 (87.5) [47.3, 99.7] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_LBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | N<10 any level | | | | | | NE |
| Europe | 9 | 8 (88.9) [51.8, 99.7] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| America | 18 | 10 (55.6) [30.8, 78.5] | 4 | 4 (100.0) [39.8, 100.0] | | | | |
| Asia/Pacific | 6 | 5 (83.3) [35.9, 99.6] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Rest of the world | 11 | 10 (90.9) [58.7, 99.8] | 6 | 5 (83.3) [35.9, 99.6] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 1 | 1 (100.0) [2.5, 100.0] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 6 | 4 (66.7) [22.3, 95.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| 25.0 - < 30.0 kg/m**2 | 18 | 14 (77.8) [52.4, 93.6] | 7 | 6 (85.7) [42.1, 99.6] | | | | |
| >= 30.0 kg/m**2 | 19 | 14 (73.7) [48.8, 90.9] | 9 | 7 (77.8) [40.0, 97.2] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.617 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| >= 150 cells/uL | 19 | 15 (78.9) [54.4, 93.9] | 9 | 8 (88.9) [51.8, 99.7] | 0.888 [0.640, 1.232] | 0.469 [0.045, 4.931] | -9.9 [-45.7, 25.8] | 1.000 |
| Baseline specific perennial FEIA status | | | | | | | | 0.487 |
| All negative | 26 | 20 (76.9) [56.4, 91.0] | 14 | 12 (85.7) [57.2, 98.2] | 0.897 [0.665, 1.212] | 0.556 [0.096, 3.207] | -8.8 [-38.7, 21.2] | 0.689 |
| Any positive | 18 | 13 (72.2) [46.5, 90.3] | 5 | 3 (60.0) [14.7, 94.7] | 1.204 [0.557, 2.602] | 1.733 [0.220, 13.670] | 12.2 [-48.2, 72.7] | 0.621 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_LBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 39 | 30 (76.9) [60.7, 88.9] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| High | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| OCS at baseline | | N<10 any level | | | | | | NE |
| Yes | 4 | 3 (75.0) [19.4, 99.4] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 40 | 30 (75.0) [58.8, 87.3] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| LAMA use at baseline | | | | | | | | 0.402 |
| Yes | 11 | 9 (81.8) [48.2, 97.7] | 7 | 5 (71.4) [29.0, 96.3] | 1.145 [0.664, 1.976] | 1.800 [0.191, 16.980] | 10.4 [-41.8, 62.6] | 1.000 |
| No | 33 | 24 (72.7) [54.5, 86.7] | 12 | 10 (83.3) [51.6, 97.9] | 0.873 [0.629, 1.212] | 0.533 [0.097, 2.921] | -10.6 [-42.3, 21.1] | 0.699 |
| Tiotropium use at baseline | | | | | | | | 0.913 |
| Yes | 9 | 7 (77.8) [40.0, 97.2] | 6 | 5 (83.3) [35.9, 99.6] | 0.933 [0.566, 1.539] | 0.700 [0.049, 10.014] | -5.6 [-59.8, 48.7] | 1.000 |
| No | 35 | 26 (74.3) [56.7, 87.5] | 13 | 10 (76.9) [46.2, 95.0] | 0.966 [0.677, 1.378] | 0.867 [0.194, 3.870] | -2.6 [-35.0, 29.7] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_LBSIK: Incidence of non-disease related TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.878 |
| Yes | 14 | 13 (92.9) [66.1, 99.8] | 6 | 6 (100.0) [54.1, 100.0] | 0.929 [0.803, 1.074] | 0.692 + [0.025, 19.431] | -7.1 [-32.5, 18.3] | 1.000 |
| No | 30 | 20 (66.7) [47.2, 82.7] | 13 | 9 (69.2) [38.6, 90.9] | 0.963 [0.619, 1.498] | 0.889 [0.219, 3.609] | -2.6 [-38.3, 33.2] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AA_LBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 9 | 8 (88.9) [51.8, 99.7] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| North America | 13 | 8 (61.5) [31.6, 86.1] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Asia Pacific | 6 | 5 (83.3) [35.9, 99.6] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Rest of the world | 7 | 7 (100.0) [59.0, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.617 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| 150 - < 300 cells/uL | 19 | 15 (78.9) [54.4, 93.9] | 9 | 8 (88.9) [51.8, 99.7] | 0.888 [0.640, 1.232] | 0.469 [0.045, 4.931] | -9.9 [-45.7, 25.8] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_LBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils (cat. Q) | | N<10 any level | | | | | | NE |
| Q1: < 140 cells/uL | 21 | 14 (66.7) [43.0, 85.4] | 10 | 7 (70.0) [34.8, 93.3] | | | | |
| Q2: 140 - < 250 cells/uL | 20 | 17 (85.0) [62.1, 96.8] | 7 | 7 (100.0) [59.0, 100.0] | | | | |
| Q3: 250 - < 430 cells/uL | 3 | 2 (66.7) [9.4, 99.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 44 | 33 (75.0) [59.7, 86.8] | 19 | 15 (78.9) [54.4, 93.9] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_LBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. Q) | | | | | | | | 0.498 |
| Q1: < 16 ppb | 22 | 17 (77.3) [54.6, 92.2] | 12 | 9 (75.0) [42.8, 94.5] | 1.030 [0.692, 1.533] | 1.133 [0.219, 5.864] | 2.3 [-34.3, 38.8] | 1.000 |
| Q2: 16 - < 30 ppb | 22 | 16 (72.7) [49.8, 89.3] | 7 | 6 (85.7) [42.1, 99.6] | 0.848 [0.571, 1.261] | 0.444 [0.044, 4.503] | -13.0 [-54.3, 28.3] | 0.646 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 33 | 27 (81.8) [64.5, 93.0] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 6 | 3 (50.0) [11.8, 88.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AA_LBSIN: Incidence of non-disease related TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 4 (100.0) [39.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 40 | 29 (72.5) [56.1, 85.4] | 18 | 14 (77.8) [52.4, 93.6] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_LBMI0: Incidence of non-disease related non-severe TEAEs during study period
DSAFNB - LTE - adult

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related non-severe TEAEs during study period | 44 | 33 (75.0) [59.7, 86.8] | 19 | 15 (78.9) [54.4, 93.9] | 0.950 [0.712, 1.267] | 0.800 [0.219, 2.927] | -3.9 [-30.1, 22.2] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table DT1AAN_LBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Sex | | | | | | | | 0.499 |
| Male | 16 | 12 (75.0) [47.6, 92.7] | 2 | 1 (50.0) [1.3, 98.7] | 1.500 [0.365, 6.172] | 3.000 [0.150, 59.890] | 25.0 [-75.6, 100.0] | 0.490 |
| Female | 28 | 21 (75.0) [55.1, 89.3] | 17 | 14 (82.4) [56.6, 96.2] | 0.911 [0.670, 1.238] | 0.643 [0.142, 2.916] | -7.4 [-36.3, 21.6] | 0.719 |
| Age | | | | | | | | 0.359 |
| < 65 years | 35 | 25 (71.4) [53.7, 85.4] | 16 | 13 (81.3) [54.4, 96.0] | 0.879 [0.641, 1.205] | 0.577 [0.135, 2.469] | -9.8 [-38.7, 19.0] | 0.730 |
| >= 65 years | 9 | 8 (88.9) [51.8, 99.7] | 3 | 2 (66.7) [9.4, 99.2] | 1.333 [0.580, 3.066] | 4.000 [0.167, 95.756] | 22.2 [-57.2, 100.0] | 0.455 |
| Exacerbations in the year before study | | | | | | | | 0.395 |
| <= 2 | 26 | 20 (76.9) [56.4, 91.0] | 11 | 8 (72.7) [39.0, 94.0] | 1.058 [0.696, 1.608] | 1.250 [0.250, 6.255] | 4.2 [-33.2, 41.6] | 1.000 |
| > 2 | 18 | 13 (72.2) [46.5, 90.3] | 8 | 7 (87.5) [47.3, 99.7] | 0.825 [0.560, 1.217] | 0.371 [0.036, 3.838] | -15.3 [-55.2, 24.6] | 0.628 |
| Race | | N<10 any level | | | | | | NE |
| White | 30 | 20 (66.7) [47.2, 82.7] | 14 | 10 (71.4) [41.9, 91.6] | | | | |
| Black or African American | 4 | 4 (100.0) [39.8, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Asian | 8 | 7 (87.5) [47.3, 99.7] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Other | 2 | 2 (100.0) [15.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_LBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region | | N<10 any level | | | | | | NE |
| Europe | 9 | 8 (88.9) [51.8, 99.7] | 6 | 3 (50.0) [11.8, 88.2] | | | | |
| America | 18 | 10 (55.6) [30.8, 78.5] | 4 | 4 (100.0) [39.8, 100.0] | | | | |
| Asia/Pacific | 6 | 5 (83.3) [35.9, 99.6] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| Rest of the world | 11 | 10 (90.9) [58.7, 99.8] | 6 | 5 (83.3) [35.9, 99.6] | | | | |
| BMI | | N<10 any level | | | | | | NE |
| < 18.5 kg/m**2 | 1 | 1 (100.0) [2.5, 100.0] | 0 | | | | | |
| 18.5 - < 25.0 kg/m**2 | 6 | 4 (66.7) [22.3, 95.7] | 3 | 2 (66.7) [9.4, 99.2] | | | | |
| 25.0 - < 30.0 kg/m**2 | 18 | 14 (77.8) [52.4, 93.6] | 7 | 6 (85.7) [42.1, 99.6] | | | | |
| >= 30.0 kg/m**2 | 19 | 14 (73.7) [48.8, 90.9] | 9 | 7 (77.8) [40.0, 97.2] | | | | |
| Baseline eosinophils - Low | | | | | | | | 0.617 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| >= 150 cells/uL | 19 | 15 (78.9) [54.4, 93.9] | 9 | 8 (88.9) [51.8, 99.7] | 0.888 [0.640, 1.232] | 0.469 [0.045, 4.931] | -9.9 [-45.7, 25.8] | 1.000 |
| Baseline specific perennial FEIA status | | | | | | | | 0.487 |
| All negative | 26 | 20 (76.9) [56.4, 91.0] | 14 | 12 (85.7) [57.2, 98.2] | 0.897 [0.665, 1.212] | 0.556 [0.096, 3.207] | -8.8 [-38.7, 21.2] | 0.689 |
| Any positive | 18 | 13 (72.2) [46.5, 90.3] | 5 | 3 (60.0) [14.7, 94.7] | 1.204 [0.557, 2.602] | 1.733 [0.220, 13.670] | 12.2 [-48.2, 72.7] | 0.621 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_LBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Total serum IgE | | N<10 any level | | | | | | NE |
| Low | 39 | 30 (76.9) [60.7, 88.9] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| High | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| OCS at baseline | | N<10 any level | | | | | | NE |
| Yes | 4 | 3 (75.0) [19.4, 99.4] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 40 | 30 (75.0) [58.8, 87.3] | 18 | 14 (77.8) [52.4, 93.6] | | | | |
| LAMA use at baseline | | | | | | | | 0.402 |
| Yes | 11 | 9 (81.8) [48.2, 97.7] | 7 | 5 (71.4) [29.0, 96.3] | 1.145 [0.664, 1.976] | 1.800 [0.191, 16.980] | 10.4 [-41.8, 62.6] | 1.000 |
| No | 33 | 24 (72.7) [54.5, 86.7] | 12 | 10 (83.3) [51.6, 97.9] | 0.873 [0.629, 1.212] | 0.533 [0.097, 2.921] | -10.6 [-42.3, 21.1] | 0.699 |
| Tiotropium use at baseline | | | | | | | | 0.913 |
| Yes | 9 | 7 (77.8) [40.0, 97.2] | 6 | 5 (83.3) [35.9, 99.6] | 0.933 [0.566, 1.539] | 0.700 [0.049, 10.014] | -5.6 [-59.8, 48.7] | 1.000 |
| No | 35 | 26 (74.3) [56.7, 87.5] | 13 | 10 (76.9) [46.2, 95.0] | 0.966 [0.677, 1.378] | 0.867 [0.194, 3.870] | -2.6 [-35.0, 29.7] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_LBSIK: Incidence of non-disease related non-severe TEAEs during study period by key subgroups
DSAFNB - LTE - adult

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| Non-disease related non-severe TEAEs during study period | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Montelukast/ Cromoglicic acid use at baseline | | | | | | | | 0.878 |
| Yes | 14 | 13 (92.9) [66.1, 99.8] | 6 | 6 (100.0) [54.1, 100.0] | 0.929 [0.803, 1.074] | 0.692 + [0.025, 19.431] | -7.1 [-32.5, 18.3] | 1.000 |
| No | 30 | 20 (66.7) [47.2, 82.7] | 13 | 9 (69.2) [38.6, 90.9] | 0.963 [0.619, 1.498] | 0.889 [0.219, 3.609] | -2.6 [-38.3, 33.2] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. OCS = oral corticosteroids. TEAE = treatment emergent adverse events. LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 11JUL2022

Table DT1AAN_LBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Region (cat. N) | | N<10 any level | | | | | | NE |
| Western Europe | 9 | 8 (88.9) [51.8, 99.7] | 7 | 4 (57.1) [18.4, 90.1] | | | | |
| North America | 13 | 8 (61.5) [31.6, 86.1] | 3 | 3 (100.0) [29.2, 100.0] | | | | |
| South America | 5 | 2 (40.0) [5.3, 85.3] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| Central/Eastern Europe | 4 | 3 (75.0) [19.4, 99.4] | 4 | 3 (75.0) [19.4, 99.4] | | | | |
| Asia Pacific | 6 | 5 (83.3) [35.9, 99.6] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Rest of the world | 7 | 7 (100.0) [59.0, 100.0] | 2 | 2 (100.0) [15.8, 100.0] | | | | |
| Baseline eosinophils (cat. N) | | | | | | | | 0.617 |
| < 150 cells/uL | 25 | 18 (72.0) [50.6, 87.9] | 10 | 7 (70.0) [34.8, 93.3] | 1.029 [0.640, 1.652] | 1.102 [0.220, 5.512] | 2.0 [-38.4, 42.4] | 1.000 |
| 150 - < 300 cells/uL | 19 | 15 (78.9) [54.4, 93.9] | 9 | 8 (88.9) [51.8, 99.7] | 0.888 [0.640, 1.232] | 0.469 [0.045, 4.931] | -9.9 [-45.7, 25.8] | 1.000 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_LBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline eosinophils (cat. Q) | | N<10 any level | | | | | | NE |
| Q1: < 140 cells/uL | 21 | 14 (66.7) [43.0, 85.4] | 10 | 7 (70.0) [34.8, 93.3] | | | | |
| Q2: 140 - < 250 cells/uL | 20 | 17 (85.0) [62.1, 96.8] | 7 | 7 (100.0) [59.0, 100.0] | | | | |
| Q3: 250 - < 430 cells/uL | 3 | 2 (66.7) [9.4, 99.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Baseline FENO (cat. N) | | N<10 any level | | | | | | NE |
| < 25 ppb | 44 | 33 (75.0) [59.7, 86.8] | 19 | 15 (78.9) [54.4, 93.9] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_LBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Baseline FENO (cat. Q) | | | | | | | | 0.498 |
| Q1: < 16 ppb | 22 | 17 (77.3) [54.6, 92.2] | 12 | 9 (75.0) [42.8, 94.5] | 1.030 [0.692, 1.533] | 1.133 [0.219, 5.864] | 2.3 [-34.3, 38.8] | 1.000 |
| Q2: 16 - < 30 ppb | 22 | 16 (72.7) [49.8, 89.3] | 7 | 6 (85.7) [42.1, 99.6] | 0.848 [0.571, 1.261] | 0.444 [0.044, 4.503] | -13.0 [-54.3, 28.3] | 0.646 |
| Total serum IgE (cat. N) | | N<10 any level | | | | | | NE |
| Q1: < 53.1 IU/ml | 33 | 27 (81.8) [64.5, 93.0] | 16 | 13 (81.3) [54.4, 96.0] | | | | |
| Q2: 53.1 - < 195.6 IU/ml | 6 | 3 (50.0) [11.8, 88.2] | 2 | 1 (50.0) [1.3, 98.7] | | | | |
| Q4: >= 572.4 IU/ml | 5 | 3 (60.0) [14.7, 94.7] | 1 | 1 (100.0) [2.5, 100.0] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAN_LBSIN: Incidence of non-disease related non-severe TEAEs during study period by study specific subgroups
DSAFNB - LTE - adult

| Non-disease related non-severe TEAEs during study period | Teze+Teze N | Teze+Teze n (%) [95 % CI] | Pbo+Pbo N | Pbo+Pbo n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
|---|---|---|---|---|---|---|---|---|
| Nasal polyps last 2 years | | N<10 any level | | | | | | NE |
| Yes | 4 | 4 (100.0) [39.8, 100.0] | 1 | 1 (100.0) [2.5, 100.0] | | | | |
| No | 40 | 29 (72.5) [56.1, 85.4] | 18 | 14 (77.8) [52.4, 93.6] | | | | |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with response. TEAE = treatment emergent adverse events.
LTE = long term extension.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = Cochran Q test for heterogeneity / exact test of Fisher. * = significant treatment effect. i = significant Cochran Q.
RR = relative risk. OR = odds ratio. RD = risk difference. + = adding of 0.5 to each cell. NE = not evaluable. Cochran Q test and risk measures are only calculated if there are at least 10 patients with events in a subgroup.
Source Data: aae, created on: 02AUG2022

Table DT1AAC_LBMI0: Incidence of non-disease related severe TEAEs during study period
DSAFNB - LTE - adult

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related severe TEAEs during study period | 44 | 5 (11.4) [3.8, 24.6] | 19 | 3 (15.8) [3.4, 39.6] | 0.720 [0.191, 2.711] | 0.684 [0.146, 3.206] | -4.4 [-27.1, 18.2] | 0.688 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022

Table DT1AAS_LBMI0: Incidence of non-disease related serious TEAEs during study period
DSAFNB - LTE - adult

| | Teze+Teze | | Pbo+Pbo | | | | | |
|---|---|---|---|---|---|---|---|---|
| | N | n (%) [95 % CI] | N | n (%) [95 % CI] | RR [95 % CI] | OR [95 % CI] | RD [95 % CI] | p-value |
| Non-disease related serious TEAEs during study period | 44 | 6 (13.6) [5.2, 27.4] | 19 | 1 (5.3) [0.1, 26.0] | 2.591 [0.334, 20.075] | 2.842 [0.318, 25.395] | 8.4 [-9.7, 26.4] | 0.664 |

Note: DSAFNB - LTE - adult = Dossier Biomarker Safety Set - predecessor NAVIGATOR - Long term extension - adults.
N = total number of patients in analysis set. n = number of patients with events.
95% CI = 95% confidence interval (percentages: Clopper-Pearson, RR/OR: Wald, RD: Newcombe method).
p-value = exact test of Fisher. * = significant treatment effect. + = adding of + 0.5 to each cell.
TEAE = treatment emergent adverse event. RR = relative risk. OR = odds ratio. RD = risk difference.
Source Data: aae, created on: 15JUL2022